葛蘭素史克 (GSK) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Welcome, everyone, and thanks for joining GSK's Q3 2026 results. Today's call will last approximately one hour with the presentation taking around 30 minutes and the remaining time for your questions. Before we begin, this slide is our usual Safe Harbor Statement. We will comment on our performance using constant exchange rates or CER, unless otherwise stated.

    歡迎各位,感謝參加GSK 2026年第三季業績說明。今天的電話會議約一小時,其中簡報約30分鐘,其餘時間將留給各位提問。在開始之前,這張投影片是我們一貫的「安全港聲明」。除非另有說明,我們將以固定匯率(CER)口徑評論我們的表現。

  • I will now hand over to Luke Miels, CEO.

    接下來我將把時間交給執行長Luke Miels。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Jeff. I'm joined today by Tony Wood, who will give an update on the pipeline; Nina Mojas, who will cover growth drivers; Julie Brown, who will cover financial performance; and David Redfern will join for Q&A. First, let's review the company performance.

    謝謝你,Jeff。今天與我一同出席的還有Tony Wood,他將更新研發管線進展;Nina Mojas,將說明成長驅動因素;Julie Brown,將說明財務表現;以及David Redfern將在問答環節加入。首先,讓我們回顧公司整體表現。

  • Next slide, please. Q3 was strong and we have continued operational momentum with sales up 5% to GBP8.9 billion. As expected, specialty is driving our momentum, including launches in respiratory and oncology. Core operating profit grew 5% and core earnings per share were up 1%. Our cash generation remains very positive at GBP7.4 billion year-to-date. Our Q3 dividend is 17p and we are on track with our responsible business rating. Given our operating momentum and launch progress, we are pleased to reconfirm 2026 guidance today. Next slide, please.

    請看下一張投影片。第三季表現強勁,我們持續保持營運動能,銷售額成長5%至89億英鎊。如預期,專科業務正驅動我們的動能,包括呼吸與腫瘤領域的新產品上市。核心營業利益成長5%,核心每股盈餘成長1%。我們的現金創造能力依然非常強勁,年初至今達74億英鎊。我們第三季股利為17便士,且在負責任企業評等方面進展符合預期。鑑於我們的營運動能與上市進度,我們很高興今天再次確認2026年財測指引不變。請看下一張投影片。

  • This slide is a reminder of our key priorities to drive value for the business and our shareholders. To start, we're focused on maximizing launches. This quarter, we've made good progress on Blenrep, where repeat prescribers are growing as physicians and patients get comfortable using the medicine, and Exdensur, where we're seeing momentum building with prescribers, patients, and access all increasing in the quarter.

    這張投影片提醒各位我們為企業與股東創造價值的關鍵優先事項。首先,我們聚焦於將上市效益最大化。本季我們在Blenrep方面取得良好進展,隨著醫師與病患逐步熟悉用藥,重複開立處方的醫師人數持續增加;而在Exdensur方面,我們也看到動能正在形成,本季開立處方者、病患數與可近性皆有所提升。

  • We've now also had our first launch in non-small cell lung cancer with Jideytro for TKI pre-treated ROS1-positive patients, which has already delivered GBP3 million. And our oncology portfolio continues to grow with a further indication for Jemperli in locally advanced rectal cancer. We also received approval for Hibsago in the US and Japan, the first finite treatment to offer a functional cure for patients with chronic hepatitis B.

    我們也在非小細胞肺癌迎來首個上市產品:Jideytro,用於接受過TKI治療的ROS1陽性患者,目前已貢獻300萬英鎊。同時,我們的腫瘤產品組合持續成長,Jemperli在局部晚期直腸癌新增適應症。我們也在美國與日本取得Hibsago核准,這是首個有限療程(finite treatment),可望為慢性B型肝炎患者帶來功能性治癒。

  • Each of these products will meaningfully contribute to near-term growth as we continue to build momentum in our specialty business. At quarter two, we outlined clear plans to accelerate R&D and we're now delivering on those plans. We are recruiting in 18 of the 22 Phase III trial starts for 2026, including two new Phase III studies for flu and the rest on track to start recruiting before the end of the year.

    隨著我們持續在專科業務建立動能,這些產品都將對短期成長做出實質貢獻。在第二季,我們提出加速研發的明確計畫,而我們目前正按計畫落實。我們正在為2026年預計啟動的22項第三期試驗中的18項進行招募,其中包含兩項新的流感第三期研究,其餘也都按進度在年底前開始招募。

  • We also presented data for several of these assets, including Jideytro, Ris-Rez, Mo-Rez and Jemperli, demonstrating significant progress in our oncology pipeline and proof points for our approach to BD. Finally, on simplification, we have made progress on the Accelerate Growth program, helping to reallocate resources to invest in R&D and accelerate our late-stage development pipeline. Fundamentally, this will align our cost base with our evolving portfolio and help us accelerate growth and deliver value for patients and shareholders.

    我們也公布了多項資產的數據,包括Jideytro、Ris-Rez、Mo-Rez與Jemperli,顯示我們腫瘤研發管線的顯著進展,並為我們的商務開發(BD)策略提供驗證。最後,在簡化方面,我們在「加速成長」計畫上取得進展,有助於重新配置資源,以加大研發投資並加速後期開發管線。從根本上而言,這將使我們的成本結構與不斷演進的產品組合相匹配,並協助我們加速成長,為病患與股東創造價值。

  • With that, I'll now hand over to Tony to cover our pipeline momentum in more detail.

    接下來我把時間交給Tony,更詳細說明我們研發管線的動能。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Thanks, Luke. It's been a busy period for R&D with a number of recent approvals and pivotal data readouts. Jideytro and Hibsago approvals were received ahead of their FDA PDUFA dates and Jemperli received accelerated approval for rectal cancer. These, together with the strength of the data presented at recent medical congresses, demonstrate the value of assets in our late-stage pipeline, where the majority have potential to be best-in-class and where we've added 12 new Phase III study starts this quarter, bringing us to 18 for the year. Next slide, please.

    謝謝你,Luke。研發近期相當忙碌,包含多項最新核准與關鍵性數據讀出。Jideytro與Hibsago均在FDA PDUFA日期之前獲得核准,而Jemperli則取得直腸癌的加速核准。這些成果,加上近期醫學會議所呈現數據的強勁表現,凸顯我們後期研發管線資產的價值;其中多數具備成為同類最佳(best-in-class)的潛力。此外,本季我們新增12項第三期研究啟動,使今年累計達18項。請看下一張投影片。

  • Moving to new products and indications. Jideytro for ROS1-positive and neladalkib for ALK-positive mutations in non-small cell lung cancer have the potential to meaningfully improve on standard of care. These mutations represent 3% to 5% of all non-small cell lung cancer. Here, patients are often younger, in their 40s and 50s, and remain on therapy for years while experiencing high rates of central nervous system side effects and often developing brain metastases.

    接著談新產品與新適應症。Jideytro用於ROS1陽性,以及neladalkib用於ALK陽性突變的非小細胞肺癌,皆有潛力在標準治療上帶來具意義的改善。這些突變約占所有非小細胞肺癌的3%至5%。在此族群中,患者往往較年輕,多在40至50多歲,且可能需接受多年治療,同時面臨較高的中樞神經系統副作用發生率,並常出現腦轉移。

  • Importantly, Jideytro is the first and only ROS1 TKI to address both selective targeting of ROS1 resistance mutations and CNS activity, thus aiming to improve treatment for patients with brain metastases while minimizing TRK-related CNS adverse events. Similarly, neladalkib is a once-a-day medicine designed to avoid off-target adverse events, which can be treatment-limiting for patients. We anticipate FDA approval in November, supported by the ALKOVE study, which showed a median progression-free survival of 14.5 months in a previously TKI-treated population.

    重要的是,Jideytro是首個且目前唯一的ROS1 TKI,能同時針對ROS1抗藥性突變進行選擇性標靶,並具備中樞神經系統(CNS)活性,因此目標是在降低TRK相關CNS不良事件的同時,改善腦轉移患者的治療效果。同樣地,neladalkib為每日一次用藥,設計上旨在避免非標的(off-target)不良事件,因其可能限制患者治療。我們預期FDA將於11月核准,並由ALKOVE研究支持;該研究在既往接受過TKI治療的人群中顯示中位無惡化存活期為14.5個月。

  • Also in oncology, approval for Jemperli in locally advanced rectal cancer is based on the AZUR-1 data, which shows 68% of participants with no detectable signs of cancer one year or more after treatment. Current standard of care achieves complete clinical response in around 20% to 25% of cases and can have lasting consequences, including bowel and urinary dysfunction and secondary cancers.

    在腫瘤領域方面,Jemperli於局部晚期直腸癌的核准係基於AZUR-1數據:顯示有68%的受試者在治療後一年或更久仍無可偵測的癌症跡象。目前標準治療的完全臨床反應率約為20%至25%,且可能造成長期後果,包括腸道與泌尿功能障礙以及次發性癌症。

  • And finally, for Hibsago, Nina will cover our launch plans for this important medicine in a moment, but I want to reiterate how transformational Hibsago will be for those living with chronic hepatitis B. These patients are at an increased risk of death from cirrhosis and liver cancer, and current treatment options involve lifelong therapy. Hibsago is the first finite treatment for chronic hepatitis B, which provides the potential for a functional cure. We plan to share additional data from the development program at AASLD in November.

    最後談到Hibsago,Nina稍後會說明這款重要藥物的上市計畫,但我想再次強調,Hibsago對慢性B型肝炎患者將具有變革性意義。這些患者因肝硬化與肝癌而死亡的風險較高,而現有治療選項通常需要終身用藥。Hibsago是首個用於慢性B型肝炎的有限療程治療,具備提供功能性治癒的潛力。我們計畫在11月的AASLD會議上分享開發計畫的更多數據。

  • Now moving to our development plans for Jideytro and neladalkib in TKI-naive patients. Jideytro data were presented at the recent World Lung Congress. The ARROS-1 response rates are amongst the highest ever reported in this patient population, with a 94% overall response rate and a 15% complete response rate. The median duration of response has not yet been reached, but 86% of patients have a duration of response of greater than 12 months.

    接著談Jideytro與neladalkib在未接受過TKI治療(TKI-naive)患者中的開發計畫。Jideytro數據已於近期世界肺癌大會(World Lung Congress)發表。ARROS-1的反應率是此患者族群中歷來報告最高之一,整體反應率達94%,完全反應率達15%。中位反應持續時間尚未達到,但有86%的患者反應持續時間超過12個月。

  • Data on brain metastases in this TKI-naive population showed no CNS progression events observed in patients without metastases at baseline and a 100% response rate in those with brain metastases at study entry. The emerging clinical profile for Jideytro suggests it has the potential to deliver meaningful outcomes as a best-in-class therapy for TKI-naive patients. Neladalkib is also in development for a TKI-naive population. And here, the Phase I/II ALKOVE study shows an 86% overall response rate.

    在此TKI-naive族群的腦轉移數據顯示:基線無轉移的患者未觀察到任何CNS惡化事件;而在入組時已有腦轉移的患者中,反應率為100%。Jideytro逐步成形的臨床特徵顯示,其有潛力作為同類最佳(best-in-class)療法,為TKI-naive患者帶來具意義的治療結果。Neladalkib也正在TKI-naive族群中開發。在此方面,第一/二期ALKOVE研究顯示整體反應率為86%。

  • Median duration of response has not yet been reached. However, 91% of patients have a duration greater than 12 months, as you can see on this slide. The corresponding Phase III TKI-naive study, ALKAZAR, is more than 50% recruited. And based on available data today, we believe neladalkib could have the potential to drive years of progression-free survival. Next slide, please.

    中位反應持續時間尚未達到。然而,如投影片所示,有91%的患者反應持續時間超過12個月。相對應的第三期TKI-naive研究ALKAZAR,招募已超過50%。基於目前可得數據,我們相信neladalkib有潛力帶來長達數年的無惡化存活期。請看下一張投影片。

  • Next for Ris-Rez, where emerging data demonstrate robust and consistent outcomes across a range of solid tumor types. In small cell lung cancer, the Chinese Phase III ARTEMIS-08 data presented at World Lung by Hansoh showed a 54% reduction in risk of death and a median overall survival of 18.5 months. The global pan-tumor Phase I/II EMBOLD-101 study has now enrolled with more than 550 patients.

    接下來談 Ris-Rez,新興數據顯示其在多種實體腫瘤類型中展現強勁且一致的療效結果。在小細胞肺癌方面,Hansoh 於世界肺癌大會(World Lung)發表的中國第三期 ARTEMIS-08 數據顯示,死亡風險降低 54%,中位總生存期為 18.5 個月。全球泛腫瘤第一/二期 EMBOLD-101 研究目前已完成入組,納入超過 550 名患者。

  • Data from the small cell lung cancer cohort of this study were presented last weekend at ESMO and showed a 61% response rate, consistent with the 58% overall response rate observed in ARTEMIS-08. The global Phase III trial, EMBOLD SCLC-301, is also recruiting well, and we anticipate preliminary data by the end of 2027. Next slide, please.

    該研究中小細胞肺癌隊列的數據於上週末在 ESMO 發表,顯示 61% 的反應率,與 ARTEMIS-08 觀察到的 58% 總反應率一致。全球第三期試驗 EMBOLD SCLC-301 也招募進展良好,我們預期在 2027 年底前取得初步數據。請看下一張投影片。

  • Also for Ris-Rez, data from the Hansoh Phase III ARTEMIS-11 study, which looked at Ris-Rez versus standard of care in Chinese patients with relapsed refractory osteosarcoma, was selected for the Presidential Symposium at ESMO this week. Osteosarcoma is a rare tumor, and relapsed patients have few treatment options. The current standard of care delivers around 2% response rate and 1.5 months of progression-free survival.

    同樣針對 Ris-Rez,Hansoh 的第三期 ARTEMIS-11 研究(比較 Ris-Rez 與標準治療,用於中國復發/難治性骨肉瘤患者)本週獲選在 ESMO 的總統研討會(Presidential Symposium)發表。骨肉瘤屬於罕見腫瘤,復發患者可用治療選擇很少。目前標準治療的反應率約為 2%,無惡化存活期約 1.5 個月。

  • In this trial, Ris-Rez demonstrated a 67% reduction in risk of disease progression or death in patients with relapsed disease. A global GSK Phase II trial, EMBOLD sarcoma-202, started earlier this year and is recruiting well. The global EMBOLD program has now over 1,000 patients who've received Ris-Rez with more than half of those enrolled in the past 8 months. Over the next 12 months, we anticipate data readouts across multiple indications, and we look forward to sharing these as they mature.

    在此試驗中,Ris-Rez 使復發患者的疾病進展或死亡風險降低 67%。全球 GSK 第二期試驗 EMBOLD sarcoma-202 於今年稍早啟動,目前招募進展良好。全球 EMBOLD 計畫目前已有超過 1,000 名患者接受 Ris-Rez,其中超過一半是在過去 8 個月內入組。未來 12 個月內,我們預期將在多個適應症取得數據讀出,並期待在數據成熟後與各位分享。

  • Next slide, please. For Mo-Rez, new data presented at ESMO from the global Phase I BEHOLD-1 trial confirms the potential for best-in-class activity in ovarian cancer with median progression-free survival of around 11 months in a non-biomarker selected population. These data compare favourably with current standard of care, which delivers around six to eight months of PFS. As promised at the accelerate growth event in July, we've now started recruitment for five Phase III trials in ovarian and endometrial cancer.

    請看下一張投影片。針對 Mo-Rez,ESMO 發表的全球第一期 BEHOLD-1 試驗新數據確認其在卵巢癌具備同類最佳(best-in-class)活性潛力:在未依生物標誌物篩選的人群中,中位無惡化存活期約 11 個月。這些數據與目前標準治療(PFS 約 6 至 8 個月)相比表現更佳。正如我們在 7 月加速成長活動中所承諾,我們現已啟動 5 項卵巢癌與子宮內膜癌的第三期試驗招募。

  • Over the next 12 months, alongside Hansoh, we will continue to generate longer-term data to demonstrate the durability, response, and safety profile of this novel ADC. Next slide, please. Also at ESMO, we presented interim pivotal results from AZUR-1, which looked at Jemperli in the treatment of patients with dMMR locally advanced rectal cancer.

    未來 12 個月內,我們將與 Hansoh 一同持續產出更長期數據,以證明這款新型 ADC 的持久性、反應與安全性特徵。請看下一張投影片。同樣在 ESMO,我們發表了 AZUR-1 的期中關鍵性(pivotal)結果;該研究評估 Jemperli 用於 dMMR 局部晚期直腸癌患者的治療。

  • The current standard of care for these patients achieves a complete clinical response in around 20% to 25% of cases, but involves chemotherapy, radiotherapy, and surgery and is associated with significant morbidity. In AZUR-1, over 2/3 of patients achieved a complete clinical response. And after a two-year follow-up period, no disease recurrences were reported amongst patients who responded. The study continues to generate data and offers an important potentially curative option for patients with locally advanced rectal cancer. Next slide, please.

    這些患者目前的標準治療可達到約 20% 至 25% 的臨床完全反應,但需接受化療、放療與手術,且伴隨顯著的罹病負擔(morbidity)。在 AZUR-1 中,超過 2/3 的患者達到臨床完全反應。且在兩年追蹤後,對於有反應的患者未通報疾病復發。該研究仍持續產出數據,並為局部晚期直腸癌患者提供一項重要、可能具治癒性的治療選擇。請看下一張投影片。

  • Turning now to vaccines. Last season, over 700,000 people, mostly older adults, were hospitalized with flu in the US Currently, flu vaccines, which generally focus on hemagglutinin, protect unevenly. Our mRNA flu vaccine candidate, which has achieved Fast Track designation from the FDA, targets both hemagglutinin and neuraminidase. Neuraminidase changes more slowly, so protection may be more durable when strains mismatch.

    接著談疫苗。上一個流感季,在美國有超過 70 萬人(多為年長者)因流感住院。目前的流感疫苗通常聚焦於血凝素(hemagglutinin),保護力不均。我們的 mRNA 流感疫苗候選產品已獲 FDA 快速通道(Fast Track)認定,並同時鎖定血凝素與神經胺酸酶(neuraminidase)。神經胺酸酶變異較慢,因此在病毒株不匹配時,保護力可能更持久。

  • Targeting both has the potential to offer broader immunity and better, more consistent protection. In Phase II, our candidate produced stronger immune responses against both targets than a high-dose comparator, supporting our decision to start a large Phase III study in more than 50,000 adults aged 65 and over. The study started in September, and more than 2/3 of this season's enrolment target has already been recruited. This study will run over two seasons, and we anticipate preliminary data next year, pending a sufficient number of cases.

    同時鎖定兩者有望提供更廣泛的免疫力,以及更佳且更一致的保護。在第二期試驗中,我們的候選產品對兩個標的皆產生比高劑量對照組更強的免疫反應,支持我們啟動一項大型第三期研究,納入超過 50,000 名 65 歲以上成人。該研究於 9 月開始,本季入組目標目前已完成超過 2/3 的招募。本研究將跨兩個流感季進行;在病例數足夠的前提下,我們預期明年取得初步數據。

  • Next slide, please. Across R&D, we continue to make fantastic progress in accelerating our late-stage pipeline. At Q2, we described our plans to start 20-plus Phase III studies in 2026. We've now started 18 Phase III studies with a further 4 on track to start before the end of the year. These studies have been accelerated based on our confidence in the differentiation and benefit to patients of our late-stage assets. I'm pleased with the continued hard work of our teams to deliver this previously unmatched pace of acceleration across a broad and growing portfolio. Next slide, please.

    請看下一張投影片。在研發方面,我們持續在加速後期研發管線上取得極佳進展。在第二季,我們說明了於 2026 年啟動 20 項以上第三期研究的計畫。目前我們已啟動 18 項第三期研究,另有 4 項按計畫將在年底前啟動。這些研究之所以能加速推進,是基於我們對後期資產差異化與對患者效益的信心。我很高興看到團隊持續努力,讓我們在廣泛且持續擴大的產品組合中,以前所未有的速度推動加速。請看下一張投影片。

  • Before I close, I momentarily want to share this slide, which we presented in July. It demonstrates the expansion of the late-stage portfolio. And from 2028 onwards, we expect to build further as we progress Phase I and II studies and continue to pursue external opportunities.

    在結束前,我想簡短分享這張我們在 7 月展示過的投影片,說明後期產品組合的擴張。並且自 2028 年起,隨著我們推進第一與第二期研究並持續尋求外部機會,我們預期將進一步擴充。

  • I'll now hand over to Nina to cover commercial performance.

    接下來我把時間交給 Nina,說明商業表現。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Thanks, Tony. Commercial momentum continued in the third-quarter, driven mainly by specialty medicines, up 15%. Our top-performing product was Cabenuva, which grew 35% in the quarter. More than 75% of switches continue to come from competitors in the US, and Cabenuva remains the only long-acting injectable regimen for HIV treatment, establishing a strong foundation with patients who prefer to take medicines less frequently.

    謝謝,Tony。第三季商業動能持續,主要由專科藥物帶動,成長 15%。我們表現最佳的產品是 Cabenuva,本季成長 35%。在美國,超過 75% 的轉換仍來自競品;Cabenuva 仍是唯一用於 HIV 治療的長效注射療程,為偏好降低用藥頻率的患者奠定了穩固基礎。

  • This is setting us up for success as we move closer to 2027 when we will have data for our three-times-a-year formulation for HIV treatment. In prevention, Apretude is performing strongly with 21% growth in the quarter and holding market share. Nucala was also a very strong contributor, up 18%, driven by the successful launch into COPD, while Exdensur continues to expand the biologic opportunity in severe asthma.

    這也為我們邁向 2027 年奠定成功基礎,屆時我們將取得每年三次給藥之 HIV 治療劑型的數據。在預防方面,Apretude 表現強勁,本季成長 21%,並維持市占率。Nucala 亦是非常重要的成長貢獻者,成長 18%,主要受惠於在 COPD 的成功上市;同時 Exdensur 持續擴大重度氣喘的生物製劑機會。

  • In oncology, we've also now launched our first medicine in non-small cell lung cancer, Jideytro. Blenrep is continuing to build as expected, while Ojjaara and Jemperli again delivered strong double-digit growth for the quarter. Vaccine performance was down 2% with the drag from Shingrix China destocking, partly offset by growth in the US We had significant growth in our meningitis portfolio, up 12%.

    在腫瘤領域,我們也已在非小細胞肺癌推出首款藥物 Jideytro。Blenrep 持續如預期推進;Ojjaara 與 Jemperli 本季再次繳出強勁的雙位數成長。疫苗業績下滑 2%,主要受 Shingrix 中國去庫存影響,部分被美國成長所抵銷。我們的腦膜炎產品組合則大幅成長 12%。

  • This was driven by strong growth from our meningitis B containing portfolio in the US, including new contributions from the first full back-to-school season for Penmenvy. And we now have over 90% share of the MenB market globally. General medicines was flat in the quarter with Trelegy performance offsetting the decline of the established portfolio. In the US, Trelegy returned to growth, up 8% as patients reached their Medicare deductibles and adjusted to coinsurance.

    這主要由我們在美國的含腦膜炎 B(MenB)產品組合強勁成長所帶動,其中包括 Penmenvy 在首個完整返校季帶來的新貢獻。目前我們在全球 MenB 市場的市占率已超過 90%。一般藥物本季持平,Trelegy 的表現抵銷了既有產品組合的下滑。在美國,隨著患者達到 Medicare 自付額並適應共同保險(coinsurance),Trelegy 重回成長軌道,上升 8%。

  • In the triple inhaler class, we maintained market leadership in COPD and asthma. However, the overall US inhaler market and SITT class continues to face price pressure. Globally, the SITT class remains the fastest-growing inhaler class, and Trelegy continues to grow double digit internationally, up 11% in the quarter. Next slide, please.

    在三合一吸入器類別中,我們在 COPD 與氣喘領域維持市場領導地位。然而,美國整體吸入器市場以及 SITT 類別仍持續面臨價格壓力。在全球範圍內,SITT 類別仍是成長最快的吸入器類別,而 Trelegy 在國際市場持續以雙位數成長,本季成長 11%。請看下一張投影片。

  • Starting with Blenrep, now approved in 52 markets, we continue to launch globally. As we are launching more broadly, we continue to see that the hands-on experience is the clearest predictor of future use, frequently changing the preexisting beliefs. In the UK, Blenrep is now the market leader in second-line for NICE-approved regimens. And in the US, HCPs are getting more comfortable with Blenrep, and repeat prescribers account for about 1/3 of sales so far and are building.

    先從 Blenrep 談起,目前已在 52 個市場獲准,我們持續在全球推進上市。隨著我們更廣泛地推動上市,我們持續看到,實際的臨床使用經驗是預測未來使用的最明確指標,且經常改變既有的看法。在英國,Blenrep 現已成為 NICE 核准療程中二線治療的市場領導者。在美國,醫療照護專業人員(HCP)對 Blenrep 的使用愈來愈熟悉,重複開立處方者目前約占銷售的 1/3,且仍在增加。

  • Recently updated NCCN guidelines recognize the full breadth of Blenrep data and include both DREAMM-7 and DREAMM-8 data in the second-line plus patient population, significantly beyond the US label. Prescribers are getting more familiar with dosing. This is leading to an improved experience with Blenrep while also extending the period between prescriptions. This extended dosing is similar to what we have in DREAMM-10 first-line study, expected to have MRD data in 2028. Next slide, please.

    近期更新的 NCCN 指南認可 Blenrep 資料的完整廣度,並在二線以上患者族群中納入 DREAMM-7 與 DREAMM-8 的資料,範圍顯著超出美國標籤適應症。處方醫師對劑量調整愈來愈熟悉。這帶來更佳的 Blenrep 使用體驗,同時也延長兩次處方之間的間隔。這種延長給藥間隔與我們在 DREAMM-10 一線研究中的做法相似,預期將於 2028 年取得 MRD 資料。請看下一張投影片。

  • Moving to respiratory. We have two key launches that have enabled GSK to gain IL-5 market leadership in a class that's up 12% versus last year. The importance of reducing exacerbations that lead to hospitalizations is the highest unmet need among physicians. And the success we are having with Nucala in COPD continues to have a halo effect across all 5 of its indications.

    接著談呼吸領域。我們有兩項關鍵上市產品,使 GSK 在 IL-5 市場取得領導地位;該類別較去年成長 12%。在醫師眼中,降低導致住院的急性惡化是最重要的未被滿足需求。我們在 COPD 適應症上 Nucala 的成功,持續對其全部 5 項適應症產生光環效應。

  • New-to-brand patients in the US is up 19% with COPD driving the majority of the growth and significant room to continue growing as only 6% of COPD patients are on a biologic. International growth continues, up 21% in the quarter. We've now achieved market leadership in China. The success we've had with Nucala and the relationships we've established with these providers has been key as we launch Exdensur.

    美國新轉用本品牌的患者增加 19%,其中 COPD 帶動了大部分成長;且仍有顯著成長空間,因為目前僅 6% 的 COPD 患者使用生物製劑。國際市場持續成長,本季成長 21%。我們現已在中國取得市場領導地位。我們在 Nucala 的成功以及與這些醫療提供者建立的關係,對於我們推出 Exdensur 至關重要。

  • Exdensur sales were GBP27 million in the quarter, with the majority of sales coming from bio-naive patients. third-quarter was a pivot point following the availability of the J-code in July and then rollout of the average selling price as of October. As a result, new prescribers in the US were up 68% in Q3, and new patient starts were up 74% when we include those who received the free first dose through our Fast Start program.

    Exdensur 本季銷售額為 2,700 萬英鎊,其中大部分銷售來自未使用過生物製劑(bio-naive)的患者。第三季是關鍵轉折點:7 月取得 J-code 後,並於 10 月開始推行平均銷售價格(ASP)。因此,美國 Q3 新增處方醫師數增加 68%;若將透過我們 Fast Start 計畫獲得免費首劑者納入計算,新啟動治療的患者數增加 74%。

  • Access continues to build with more than 2/3 of insured patients now being covered. And significant growth opportunity remains as around 17% of patients who could be on a biologic for severe asthma still are not. Next slide, please. Finally, I wanted to share further details on our launch plans for Hibsago. In Japan, chronic hepatitis B is a government priority, and there are already established processes in place and guidelines that support functional cure.

    可近性持續提升,目前已有超過 2/3 的投保患者獲得給付涵蓋。同時仍存在顯著成長機會,因為約有 17% 可能適用於重度氣喘生物製劑治療的患者仍未使用。請看下一張投影片。最後,我想分享我們針對 Hibsago 的上市計畫更多細節。在日本,慢性 B 型肝炎是政府優先事項,且已建立相關流程與指引以支持功能性治癒。

  • Since approval, we have received a very positive reimbursement decision, and physicians have already identified patients to receive therapy. In the US, chronic hepatitis B is very concentrated with the majority of patients in five states. We have launched with a focus on patients with surface antigen level lower than 1,000, where the opportunity to have a positive experience leading to functional cure is the highest.

    自獲准以來,我們已獲得非常正面的給付決策,且醫師已經辨識出將接受治療的患者。在美國,慢性 B 型肝炎患者高度集中,多數患者位於五個州。我們的上市策略聚焦於表面抗原水準低於 1,000 的患者族群,因為在此族群中,獲得正向治療體驗並進而達到功能性治癒的機會最高。

  • The US, Japan, and China represent around 80% of the potential value for Hibsago. Following the approvals in Japan and the US, we look forward to hearing from regulators in China, where managing chronic hepatitis B is a national priority and where we have established a strategic collaboration with Sino Biopharmaceutical, a recognized leader in hepatology in China.

    美國、日本與中國約占 Hibsago 潛在價值的 80%。在日本與美國獲准後,我們期待聽取中國監管機關的意見;在中國,慢性 B 型肝炎管理是國家優先事項,我們也已與中國肝病領域公認的領導者——中國生物製藥(Sino Biopharmaceutical)建立策略合作。

  • I'll now hand over to Julie.

    接下來我把時間交給 Julie。

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Thank you, Nina. I will now cover financial performance with growth rates at CER, unless otherwise stated. Next slide, please. Starting with the income statement for the quarter. Sales grew 5%. Gross profit was up 7%, supported by product mix and efficiencies. SG&A increased 1%, including Nuvalent costs, demonstrating smart resource allocation and improved ROI.

    謝謝你,Nina。接下來我將說明財務表現;除非另有說明,成長率皆以 CER(固定匯率)計。請看下一張投影片。先從本季損益表開始。銷售成長 5%。毛利成長 7%,受惠於產品組合與效率提升。SG&A 增加 1%,包含 Nuvalent 相關成本,展現更聰明的資源配置與更佳的投資報酬率(ROI)。

  • And R&D grew 22%, in line with our accelerate growth agenda outlined at Q2 with a further 12 Phase III trials initiated this quarter. Growth was driven primarily by accelerated oncology spend on Ris-Rez, Mo-Rez and velzatinib, as well as further investment in felcorekibart and efimosfermin. Operating profit grew 5% with the margin broadly stable as increased R&D investment was broadly offset by cost of goods and SG&A productivity as we further match our cost base to the evolving portfolio.

    研發(R&D)成長 22%,符合我們在 Q2 所提出的加速成長議程;本季另啟動 12 項第三期(Phase III)試驗。成長主要由腫瘤領域支出加速所帶動,涵蓋 Ris-Rez、Mo-Rez 與 velzatinib,並包含對 felcorekibart 與 efimosfermin 的進一步投資。營業利益成長 5%,利潤率大致持平;增加的研發投資大致被銷貨成本與 SG&A 生產力提升所抵銷,因我們進一步使成本基礎與不斷演進的產品組合相匹配。

  • EPS was up 1% with the differential due to increased interest costs following the Nuvalent acquisition and a higher tax rate in the quarter. Turning to total results. The quarter was impacted by GBP0.3 billion accelerate growth charge with the program to simplify and reallocate spend towards R&D now well underway. We're moving at pace and ahead of schedule.

    每股盈餘(EPS)成長 1%,差異主要來自 Nuvalent 收購後利息成本增加,以及本季較高的稅率。接著看整體結果。本季受到 3 億英鎊加速成長費用的影響;簡化並將支出重新配置至研發的計畫目前已全面展開。我們正以快速步調推進,且進度超前。

  • And since July, we have initiated a series of changes across the organization to streamline support services, simplify our supply chain, and reallocate resources. And we now expect charges of up to GBP1 billion in 2026. Next slide, please. Moving to cash generation. Year-to-date performance has been strong. CGFO was GBP1.1 billion ahead of last year, underpinned by business performance with increased operating profit and favorable working capital movements.

    自 7 月以來,我們已在全組織啟動一系列變革,以精簡支援服務、簡化供應鏈並重新配置資源。我們目前預期 2026 年的相關費用最高可達 10 億英鎊。請看下一張投影片。接著談現金創造。年初至今表現強勁。營運活動現金流(CGFO)較去年增加 11 億英鎊,主要由業務表現支撐,包括營業利益增加以及營運資金變動有利。

  • And as a reminder, the year-on-year comparison was impacted by GBP0.7 billion Zantac cash outflow in 2025 and a net headwind of GBP0.2 billion from the CureVac settlements. Turning to free cash flow. It was up GBP1.8 billion year-to-date, including $650 million from the out-license of linerixibat and the special dividend received due to the ViiV shareholding change. Looking forward to the full year, we remain on track to deliver our target of around GBP10 billion CGFO at constant rates.

    提醒一下,年對年比較受到 2025 年 7 億英鎊 Zantac 現金流出影響,以及 CureVac 和解帶來 2 億英鎊的淨逆風。接著看自由現金流。年初至今增加 18 億英鎊,其中包含 linerixibat 對外授權帶來的 6.5 億美元,以及因 ViiV 持股變動而收到的特別股利。展望全年,我們仍按計畫達成以固定匯率計約 100 億英鎊 CGFO 的目標。

  • Next slide, please. Over the past years, we have significantly improved cash generation, conversion of profit to cash, and the strength of the balance sheet. This has enabled targeted business development to strengthen our late-stage pipeline. And most recently, with the acquisition of Nuvalent, whilst retaining capacity within a strong balance sheet with net debt to core EBITDA at 1.8x.

    請看下一張投影片。過去幾年,我們顯著改善了現金創造、獲利轉換為現金的能力,以及資產負債表的強度。這使我們得以進行具針對性的業務發展,以強化後期研發管線。而最近透過收購 Nuvalent,我們在維持強健資產負債表的同時仍保有財務彈性,淨負債對核心 EBITDA 比率為 1.8 倍。

  • Next slide, please. Looking ahead, we remain on track to deliver our full year 2026 guidance. Sales are expected in the upper half of the range, driven by specialty performance. Core operating profit is also expected in the upper half of the range, and margin remains on track to be more than 31% at constant rates. This is enabled by SG&A, which is projected to be broadly stable, cost of goods benefits from product mix and efficiencies, and royalties, which are now upgraded to around GBP900 million for the year.

    下一張投影片,請。展望未來,我們仍按計畫達成2026全年指引。在專科業務表現帶動下,銷售預期落在區間的上半部。核心營業利益亦預期位於區間上半部,且在固定匯率下,利潤率仍按計畫將超過31%。這得益於SG&A預計大致維持穩定、產品組合與效率帶來的銷貨成本效益,以及權利金(royalties)目前上調至全年約9億英鎊。

  • Whilst R&D is expected to grow significantly ahead of sales for the year as we more than double the number of Phase III starts from the 10 expected at the start of the year to now 22. EPS growth is expected to be in the low half of the range, with full year interest expected to be GBP700 million to GBP750 million, including around GBP160 million relating to the acquisition of Nuvalent.

    同時,研發(R&D)預期全年將顯著快於銷售成長,因為我們將第三期(Phase III)啟動數量從年初預期的10項提高到目前的22項,超過翻倍。每股盈餘(EPS)成長預期落在區間的下半部;全年利息費用預期為7億至7.5億英鎊,其中包含約1.6億英鎊與收購Nuvalent相關。

  • With respect to currency, we now expect foreign exchange headwinds of minus 1% on sales and minus 3% on operating profit. And finally, looking ahead, we remain committed to our long-term outlook. And in the appendix, you will find modelling considerations to the end of this year and into next. Thank you.

    就匯率而言,我們目前預期外匯逆風對銷售為-1%,對營業利益為-3%。最後,展望未來,我們仍致力於長期展望。在附錄中,您將看到至今年底以及延伸至明年的建模考量。謝謝。

  • And with that, I'm pleased to hand back to Luke.

    接下來,我很高興把時間交還給Luke。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Julie. To close, we remain focused on executing our strategy, which is built on driving top-line growth, building and accelerating the late-stage portfolio and actively reallocating resources to where they can create the largest value for patients and shareholders. We'll now open for Q&A.

    謝謝,Julie。最後,我們仍專注於執行策略:推動營收成長、建立並加速後期產品組合,並積極將資源重新配置到能為病患與股東創造最大價值之處。現在我們開放問答(Q&A)。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • (Event Instructions)

    (活動說明)

  • James Gordon, Barclays

    James Gordon,巴克萊(Barclays)

  • James Gordon - Analyst

    James Gordon - Analyst

  • Hi, James Gordon from Barclays. First question was on HIV and next-generation injectables and also more broadly, what's going on in HIV or ViiV. So I read there was an update about CAB 4-monthly PrEP and that you've got the data in-house and PK analysis is still underway. But how should we read that? Does that mean you've got to do a bit more work on the PK equivalents? Are there questions there? And could that delay the launch?

    嗨,我是巴克萊的James Gordon。第一個問題是關於HIV與下一代注射劑,更廣泛來說,是HIV或ViiV目前的情況。我看到有更新提到CAB每四個月一次的PrEP,你們已取得內部數據,且藥物動力學(PK)分析仍在進行中。但我們應該如何解讀?這是否表示你們還需要在PK等效性上再做一些工作?那裡是否存在疑問?這會不會延後上市?

  • I think there was a comment about the data next year, but do you still think you could launch on the same time lines? And is there any read-through because I believe it's the same tech for four-monthly Apretude as four-monthly Cabenuva. So could there be a delay or any extra work you've got to do there?

    我想之前有提到明年會有數據,但你們仍認為可以在相同時間表上推出嗎?另外,是否有任何可推論之處,因為我相信每四個月一次的Apretude與每四個月一次的Cabenuva使用的是相同技術。所以是否可能延遲,或需要做任何額外工作?

  • And the broader question in HIV, there's been quite a few management changes. So ViiV's CEO and CFO and fairly recent R&D change. So is this at all connected? Is there a trend there? Any implications? Is there any sort of reboot going on in HIV since Luke became CEO?

    而在HIV更廣泛的問題上,管理層變動不少。ViiV的CEO與CFO,以及相對近期的研發(R&D)變動。這之間是否有任何關聯?是否有某種趨勢?有任何影響嗎?自從Luke成為CEO以來,HIV業務是否正在進行某種「重啟」?

  • And then the second question was just on new launches. So Exdensur and Blenrep, and I've heard comments about you've now got the J-code, I think it was from the beginning of July. Was that the key thing that was holding up the launches? And do you now think we're going to see a big acceleration, a big inflection into next year? Or might we need to wait a little bit longer because there's some other things you also need to really see those products accelerate?

    第二個問題是關於新產品上市。像是Exdensur和Blenrep,我聽到一些評論說你們現在已經拿到J-code,我想是從7月初開始。這是否是之前拖延上市的關鍵因素?你們現在是否認為我們將看到明顯加速、在明年出現顯著拐點?或者我們可能還需要再等一段時間,因為還有其他因素必須到位,這些產品才會真正加速?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Great. Thanks, James. I think you've done your colleagues a favour because I suspect we'll be able to capture a number of themes there. So why don't we do the ViiV questions first? I'll just say something quickly, then we'll go to David and then Nina, if you can cover Exdensur and Blenrep. Look, I think, firstly, no connection to management changes. I mean the fact is that Deborah got a promotion to be the CEO of CSL. These things don't come along every day. And I think that's great news for Deborah.

    很好。謝謝你,James。我想你幫了你的同事一個忙,因為我猜我們可以在這裡涵蓋不少主題。那我們先回答ViiV的問題?我先簡短說幾句,接著交給David,然後Nina,如果你能涵蓋Exdensur和Blenrep。首先,我認為這與管理層變動沒有關聯。事實上,Deborah獲得晉升,成為CSL的CEO。這種機會不是天天都有。我認為這對Deborah來說是很棒的消息。

  • And actually, I just want to personally thank her for her years as GSK as a peer and a team member. And as an Australian, I hope she does very well at CSL, just not too well on the vaccine side. Lynn Baxter, who stepped in. So it was a very quick process. Pretty much as soon as I got the phone call from Deborah, I called Lynn. Lynn ran the US ViiV business, and she launched the long-acting products, and she has been on the ViiV Board during this time. So she's very much up to date.

    而且我也想以個人名義感謝她在GSK多年來作為同儕與團隊成員的付出。身為澳洲人,我希望她在CSL表現非常好,只是疫苗業務方面不要太好。接任的是Lynn Baxter。所以這是一個非常快速的流程。幾乎在我接到Deborah電話後,我就打給Lynn。Lynn曾負責美國ViiV業務,並推出長效產品,而且這段期間她一直在ViiV董事會任職。因此她對現況非常熟悉。

  • It was an easy decision. And I've known Lynn for a long time since my Roche days. Kim retired, remember, and Charlotte stepped in, and she remains the Head of ViiV R&D. And Charlotte worked with Tony at Pfizer. And as I think you all saw at Q2, she knows what she's doing. So I feel very comfortable there. I think more broadly, operationally, I want ViiV to be closer. And so there will be more intensive interaction and supervision there, but that's not a bad thing.

    這是個容易的決定。我從在Roche的時期就認識Lynn很久了。Kim退休了,大家記得,而Charlotte接任,她仍是ViiV研發負責人。Charlotte曾在輝瑞(Pfizer)與Tony共事。而且我想你們在第二季(Q2)也都看到,她很清楚自己在做什麼。所以我對此非常放心。更廣泛來說,在營運上,我希望ViiV能更貼近。因此會有更密集的互動與督導,但這不是壞事。

  • Secondly, before I hand to you, David, I just wanted to make a broader point about how we want to communicate with the owners of the company and you as analysts and, I guess, the market more broadly. Look, we're going to call things as we see them.

    第二點,在交給你之前,David,我也想就我們希望如何與公司所有者、你們作為分析師,以及我想更廣泛的市場溝通,做一個更宏觀的說明。我們會如實說明我們所看到的情況。

  • And we're not going to park crap on page 41 of a press release and hope none of you notice it. So we'll tell you as much as we can. We will have a plan to address it. But please just adjust your parameters on that because that's how we want to operate. All right. So with that, David, over to you. Tony, feel free to add anything.

    我們不會把爛事塞在新聞稿第41頁,然後希望你們都沒注意到。所以我們會盡可能告訴你們更多。我們也會有計畫來處理。但請你們就此調整你們的假設參數,因為這就是我們想要的運作方式。好。那麼,David,交給你。Tony,也歡迎補充。

  • David Redfern - Chief Strategy Officer

    David Redfern - Chief Strategy Officer

  • Thanks, Luke. I mean the first thing I want to do actually is just echo what Luke said around Deborah. I mean she led ViiV incredibly strongly through almost 10 years, obviously drove a huge amount of growth through that time, not least this year, where ViiV is up 10% in the quarter and for the year. And as Luke said, I mean, Lynn Baxter may not be particularly well known to the investment community, but she's very well-known inside GSK, very distinguished leader with experience on both sides of the Atlantic.

    謝謝,Luke。其實我首先想做的是呼應Luke對Deborah的說法。她在將近10年的時間裡非常有力地領導ViiV,顯然在這段期間推動了大量成長,尤其是今年,ViiV本季成長10%,全年也是成長10%。如Luke所說,Lynn Baxter對投資界可能不是特別為人所知,但在GSK內部她非常知名,是一位資歷深厚的領導者,並且在大西洋兩岸都有經驗。

  • She led ViiV North America for 6 years, so very connected in the HIV community in America. And obviously, during that time, introduced the long-acting medicines to the US market. And as Luke said, Lynn plus Charlotte Allerton, plus Jean van Wyk, who's the Chief Medical Officer and very well known in the HIV community. I'm very confident in the strength right through the ViiV management team.

    她領導ViiV北美業務6年,因此在美國HIV社群中連結非常深。而且顯然在那段期間,將長效藥物引進美國市場。如Luke所說,Lynn加上Charlotte Allerton,再加上首席醫務官Jean van Wyk(在HIV社群中也非常知名)。我對ViiV整個管理團隊自上而下的實力非常有信心。

  • James, I mean, in terms of the pipeline, I mean, not much more to say at this point on EXTEND4M. We have the data in-house. The analysis is ongoing. We look forward to sharing with the regulators. And obviously, we will update the market once that analysis is complete. What I would say is we're very pleased with the progress we're making with the treatment pipeline in parallel.

    James,我的意思是,就研發管線而言,關於 EXTEND4M 目前沒有太多可以補充的。我們已在內部取得數據。分析仍在進行中。我們期待與監管機關分享。而且很明顯地,一旦分析完成,我們會更新市場。我想說的是,我們對於同步推進治療研發管線所取得的進展感到非常滿意。

  • So the first thing I'd call out actually for Cabenuva is the Phase IIIb CROWN study where we've shown the headline that showed superiority of Cabenuva in an unsuppressed viremic population compared to daily oral standard of care. And that's important because in the US, there's probably about 40% of the market is unsuppressed, so over 400,000 people. So that's people living with HIV. So that's a significant growth opportunity.

    所以我首先想特別指出 Cabenuva 的部分,其實是第三期 b 期 CROWN 研究;我們已公布重點結果,顯示在未受抑制的病毒血症族群中,Cabenuva 相較於每日口服的標準治療具有優越性。這很重要,因為在美國,市場中大約有 40% 屬於未受抑制族群,超過 40 萬人。也就是 HIV 感染者。因此這是一個顯著的成長機會。

  • We will show that data at future congress, and we will also update the regulators and apply for a label expansion on that. And just to remind you, that's actually the second superiority study of Cabenuva. We had LATITUDE earlier in patients, people living with HIV with adherence challenges. So great progress with Cabenuva.

    我們會在未來的學術會議上展示這些數據,也會向監管機關更新,並就此申請擴大適應症標籤。另外提醒一下,這其實是 Cabenuva 的第二項優越性研究。先前我們在有服藥依從性挑戰的 HIV 感染者族群中做過 LATITUDE。所以 Cabenuva 的進展非常好。

  • And then with the four-monthly formulations of cabotegravir and rilpivirine, I'm pleased to say the CUATRO study recruited very fast over the summer ahead of our expectations. It's been fully recruited now for a number of weeks. The readout is at month 11. Just to remind you, it is an efficacy study comparing four months with two-monthly Cabenuva, but that's obviously now very much on track to read out next year.

    接著談到 cabotegravir 與 rilpivirine 的每四個月一次劑型,我很高興地說,CUATRO 研究在夏季的招募速度非常快,超出我們的預期。目前已完成招募,且已經維持了好幾週。讀出時間點在第 11 個月。提醒一下,這是一項療效研究,比較每四個月一次與每兩個月一次的 Cabenuva;但很明顯地,目前進度非常順利,預計明年讀出。

  • And we continue to make progress with the six-monthlies 184 and 499 that are progressing as planned through Phase II, and we still intend to start a pivotal study with that combination with six-monthly, which we're very excited about in 2028.

    我們也持續推進每六個月一次的 184 與 499,按計畫在第二期試驗中進展;我們仍打算以這個每六個月一次的組合在 2028 年啟動關鍵性試驗,對此我們非常興奮。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Great. Thanks, David. I'm sure we'll get some more questions on that. Anything you wanted to.

    很好。謝謝你,David。我相信我們還會收到更多相關問題。你還有什麼想補充的嗎?

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Just a couple of very quick points. Look, first of all, Charlotte is a very experienced pharmacokineticist and R&D leader. You saw that at Q2. And I just want to underscore, we see no read-through to the treatment portfolio.

    我只想很快補充兩點。首先,Charlotte 是非常有經驗的藥物動力學專家與研發領導者。你們在第二季已經看到了。而我想強調的是,我們認為這不會對治療產品組合產生任何延伸影響(read-through)。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Tony. Nina?

    謝謝,Tony。Nina?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • So Exdensur and Blenrep. Exdensur, very specific question, J-code, has that been a milestone or a change? So for Exdensur, I'm actually pretty confident that, yes. Just for background, we got the J-code 1 of July, maybe a little bit more technical. Usually with J-code, the team gets something that we call the ASP document, which is average selling price document that can be shared with the physician, so they're aware of what the price -- what is the price that will be reimbursed to them.

    那我來談 Exdensur 和 Blenrep。關於 Exdensur,有個很具體的問題:J-code,這是否算是一個里程碑或帶來改變?就 Exdensur 而言,我其實相當有信心,答案是肯定的。補充背景:我們在 7 月 1 日取得 J-code,這可能稍微技術性一點。通常取得 J-code 後,團隊會拿到我們稱為 ASP 文件(平均銷售價格文件),可提供給醫師,讓他們了解價格——也就是將會給付給他們的可報銷價格。

  • That document became available on the 1 of October. All of that said, the numbers that we shared in Q3, we have seen significant increase in the new prescribers. So 68% new prescribers and then 74% new patient starts. That includes the totality of both sold volume and the free goods volume that is part of our Fast Start. Another piece to remember, Q3 because of the summer tends to be the quarter that has the lowest number of patient visits.

    該文件在 10 月 1 日開始可取得。總之,我們在第三季分享的數據顯示,新開立處方的醫師數量顯著增加。也就是 68% 為新處方醫師,且 74% 為新病人開始用藥。這包含我們 Fast Start 計畫中的總銷售量與免費供藥量的整體合計。另外要記得的是,第三季因為暑期因素,通常是病人就診次數最少的一季。

  • And as that ASP document became available as of 1 of October, obviously, you don't see the sales after that. I can just maybe mention every week since then has been the highest week of sales for Exdensur one after another with the last week being the high sales. So yes, definitely for Exdensur, this has been a milestone kind of moment, and we do expect to see a change in trend from now on. All of that said, it still remains, it's the first long-acting and there has to be adjustment to that, but definitely very, very positive moments.

    而由於 ASP 文件是在 10 月 1 日才開始可取得,很明顯地,你們在第三季還看不到那之後的銷售表現。我可以補充的是,自那之後每一週都創下 Exdensur 史上最高的單週銷售,一週接著一週,最新一週又是最高。所以是的,對 Exdensur 來說,這確實是一個里程碑式的時刻,我們也預期從現在起會看到趨勢改變。儘管如此,它仍是第一個長效型產品,市場需要時間調整,但這些都是非常、非常正面的時刻。

  • Maybe just to add, this is the time when we start seeing patients coming back. So it's six-monthly. So you would start seeing patients after six months receiving again another shot, which is our whole benefit of Exdensur that patients remain on therapy for a long time. It's a very small number of patients that is reaching that point, but the numbers that we see are actually very encouraging. So let's see if that holds as more and more patients get to six-monthly mark.

    再補充一點,現在也正是我們開始看到病人回診的時間點。因為它是每六個月一次。所以在六個月後,你會開始看到病人再次回來接受下一針;這正是 Exdensur 的核心效益——病人能長期維持治療。目前達到這個時間點的病人數仍然很少,但我們看到的數字其實非常令人鼓舞。所以讓我們看看,隨著越來越多病人到達六個月時間點,這個趨勢是否能持續。

  • Blenrep, the way I would describe Blenrep, you have seen now that about half of the sales are coming from ex-US and that reflects, again, that more experience existing ex-US, both in the clinical setting and in the commercial setting. The previous experience is the most relevant factor when it comes to prescribing Blenrep, and that's reflected ex-US, a lot of learnings ex-US that can be moved to the US.

    至於 Blenrep,我會這樣描述:你們現在看到大約一半的銷售來自美國以外市場(ex-US),這再次反映出在美國以外地區,無論在臨床端或商業端,都累積了更多使用經驗。在開立 Blenrep 處方時,既有使用經驗是最相關的因素;而這點在美國以外市場有所體現,也有許多美國以外的學習可移轉到美國。

  • So we are intensifying peer-to-peer exchange in the US, those who have experience to potentially impact the perceptions. I would probably say that the pre-existing perception of Blenrep is the biggest challenge rather than anything else. And we are -- we have a number of activities that are hopefully going to work to change that.

    因此我們正在美國加強同儕對同儕(peer-to-peer)的交流,讓有經驗的人能夠潛在地影響市場觀感。我可能會說,Blenrep 最大的挑戰是既有的市場印象,而不是其他因素。而我們——我們正在進行多項活動,希望能夠改變這種印象。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Simon Baker, Redburn.

    Simon Baker,Redburn。

  • Simon Baker - Analyst

    Simon Baker - Analyst

  • Two, if I may, please. Firstly, on Shingrix. I wonder if you could just dig down a little bit into the pushes and pulls within the various regions. We do see quite a divergent performance across the world. And related to that, perhaps you could give us an update also on the potential accelerants for Shingrix growth going forward. Firstly, the MACE opportunity and then beyond that, the dementia potential indication.

    如果可以的話,我有兩個問題。第一個關於 Shingrix。我想請你們更深入談談各地區之間的推力與拉力因素。我們確實看到全球各地表現差異相當大。此外,也許你們可以更新一下未來推動 Shingrix 成長的潛在加速因素。首先是 MACE 的機會,然後再往後是失智症的潛在適應症。

  • And then second question on Hibsago. Given this is the first treatment for a very long time in that indication, perhaps, you could give us an idea of how we should think about the trajectory and also the initial prescriber reaction to the profile of the product and the label. We've had a few people questioning the monitoring. I'm wondering in the real world, how much of that really, is that really a barrier to adoption?

    第二個問題關於 Hibsago。鑑於這是在該適應症領域相隔很長時間後的第一個治療選項,也許你們可以談談我們應該如何看待其成長軌跡,以及處方醫師對產品特性與標籤的初期反應。我們聽到有些人對監測要求提出疑問。我想了解在真實世界中,這在多大程度上真的是採用的障礙?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Thanks, Simon. So what we would do, thank you. I'll cover the Shingrix component. And then, Tony, you can cover the acceleration, sorry, yes, the acceleration and basically MACE dementia. And then after that, we'll come back to Hibsago. So Simon, how would I go region by region and call out if I confuse you. So for the US, the IZ rate is 46%, which is up 3-percentage-points, which is in the middle of the 2% to 4% range that we said that we would get in a year.

    好的,謝謝你,Simon。那我們會這樣安排,謝謝。我先回答 Shingrix 的部分。然後 Tony,你可以談加速因素——抱歉,是的,加速因素以及基本上 MACE 與失智症。之後我們再回到 Hibsago。Simon,我會按地區逐一說明;如果我講得讓你困惑,請提醒我。就美國而言,IZ 接種率是 46%,上升了 3 個百分點,這落在我們所說一年可提升 2% 到 4% 的區間中間值。

  • TRX is okay, and we've got slightly stronger NBRx. The key thing is we're seeing stronger penetration now in the health care system. So this is the comorbid population, so we're getting some traction there. But we do need to balance that with the fact that the adult market overall, adult vaccines market overall is still challenging. Now Shingrix is doing a little bit better in relative terms. So the adult market is down about 18% versus this time last year, but Shingrix is down about 14%.

    TRX 還可以,而且我們的 NBRx 略為更強。關鍵是我們現在看到在醫療體系中的滲透率更強。這是共病族群,所以我們在那裡取得了一些進展。但我們確實需要在這點與整體成人市場、整體成人疫苗市場仍具挑戰性的事實之間取得平衡。目前 Shingrix 相對而言表現稍微好一些。因此,成人市場較去年同期下滑約 18%,但 Shingrix 下滑約 14%。

  • Inventory is usually a question we get. Wholesalers are steady at 0.4, same as last year. But the pharmacists have been buying. And so the stock level is higher right now in pharmacy. It's around 2.3 million versus 1.7 million doses this time last year. And that's likely driven by the fact that we've got a later flu season. So we'll get a clearer picture in Q4. So that's the US.

    庫存通常是大家會問的問題。批發商維持在 0.4,與去年相同。但藥局端一直在進貨。因此目前藥局的庫存水位較高。大約是 230 萬劑,相較於去年同期的 170 萬劑。這很可能是因為流感季來得較晚所致。所以我們會在第四季看到更清楚的情況。以上是美國。

  • China is, I think it's steady improvement is how I would describe it. So the key is in-arm demand. So we're doing about 300,000 shots a month, and that's up 60% versus last year. So I would say that's steady growth over time. And it seems to be pretty resilient despite the structural CDC ordering stock management challenges. And remember, we called this early when it was slowing down in 2024. And look, we're basically doing what we said we would do, which is to work off the volume in the pipe.

    中國方面,我會形容為穩步改善。關鍵在於實際接種需求(in-arm demand)。我們每月大約施打 30 萬針,較去年成長 60%。所以我會說這是隨時間推進的穩健成長。而且即使面臨 CDC 訂購與庫存管理的結構性挑戰,看起來仍相當有韌性。也請記得,我們在 2024 年放緩時就很早提出了這點。而且你看,我們基本上是在做我們說過會做的事,也就是消化管道中的量。

  • And the inventory has dropped. So there was, summer last year was around 4.3 million doses and now we're down to 1.4 million doses as of August. So that's about 1.5 months of demand. So that's about as low as you would want it. So I would expect ideally, next year, we do a reorder. But again, we're not doing mass shipments. We want to sort of match the demand, knowing it's quite a, we've got quite a long time frame between shipping and actually being distributed in China that we also need to manage.

    而庫存已經下降。去年夏天大約是 430 萬劑,而截至 8 月現在降到 140 萬劑。這大約相當於 1.5 個月的需求。所以這差不多是你希望看到的最低水位。因此我理想上預期明年會再下單補貨。但同樣地,我們不會做大量出貨。我們希望大致匹配需求,因為我們知道從出貨到在中國實際分發之間的時間跨度很長,這也需要管理。

  • So the rest of the world is, again, it's about nearly, well, it's about 60% of sales. So again, solid. For the EU, it's really expansion in new countries, broader coverage. Private demand also is starting to increase, which is encouraging. We did have a bit of a softer time in Germany and France in summer. We think that's partly due to the heat, but also there's some parallel trade impact.

    至於世界其他地區,同樣地,約占銷售額的將近——嗯,大約 60%。所以同樣是穩健的。在歐盟,主要是擴展到新國家、提高更廣泛的覆蓋。私人需求也開始增加,這令人鼓舞。我們在夏季於德國和法國確實稍微疲弱一些。我們認為部分原因是高溫,但也有一些平行貿易的影響。

  • And then on the rest of international, it's very much expansion and really driving access in markets like Brazil, Turkey, other markets like that, and Saudi. Tony, did you want to, sorry, Simon, long answer, but a broad question. Did you want to cover the dementia and MACE, and then we'll go to Nina.

    然後在其他國際市場方面,重點非常在於擴張,並真正推動在巴西、土耳其、以及沙烏地等市場的可近性。Tony,你要不要——抱歉,Simon,回答有點長,但問題很廣。你要不要談一下失智症和 MACE,然後我們再交給 Nina。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • You bet. Thanks for the question, Simon. So look, we've got a broad range of work going on, looking at both the MACE and dementia aspects for Shingrix, including mechanistic studies and pragmatic RCTs. There are two of those going on, Simon, in Finland and Denmark, looking to enrol about 200,000 adults, and we're expecting initial results from those 2 studies in 2029.

    當然。謝謝你的問題,Simon。我們正在進行一系列廣泛的工作,針對 Shingrix 的 MACE 與失智症兩個面向,包括機轉研究與務實性 RCT(pragmatic RCTs)。目前有兩項這類研究正在進行中,Simon,分別在芬蘭與丹麥,目標納入約 20 萬名成人,我們預期這兩項研究在 2029 年會有初步結果。

  • We'll have a first readout on the CVD data at the end of 2027. These are Finland where we're evaluating the effect of Shingrix on dementia in greater than 76-year-olds. That's with the registry-based diagnosis in Denmark, where we're evaluating the effect on risk of MACE and in dementia, in that case, in 65-plus population. For MACE stand-alone, we're at the moment, expecting to be able to start a study by the end of the year. We have ongoing discussions with regulators at this point in time, but we, this will be a very broad study in 28 countries, and we've selected already 750 sites, so well underway.

    我們會在 2027 年底先看到 CVD 數據的首次讀出。其中芬蘭的研究是在評估 Shingrix 對 76 歲以上族群失智症的影響。丹麥則是以登錄資料(registry)為基礎的診斷,評估對 MACE 風險以及失智症的影響;在那個研究中,族群是 65 歲以上。至於單獨針對 MACE 的研究,我們目前預期可在今年底前啟動。我們此刻仍在與監管機關持續討論,但這將是一項涵蓋 28 個國家的大型研究,我們已選定 750 個研究中心,因此進展相當順利。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Hibsago. So, Hibsago was approved in Japan and the US Regulatory discussions are ongoing very intensely in China. So that's the next one to come. So Japan, we got the reimbursement. I think one of the testaments to Hibsago uniqueness is reimbursement in Japan was justified by the regulators with 50% usefulness premium, which is a number that you hardly see in Japan and then additional 10% premium for SENKU designation. So very, very happy with that conversation.

    Hibsago。Hibsago 已在日本與美國獲准,目前在中國也正非常密集地進行監管討論。所以它會是下一個。在日本,我們已取得給付。我認為 Hibsago 獨特性的其中一個證明是:日本的給付是由主管機關以 50% 的有用性加成(usefulness premium)作為合理化依據,這在日本是很少見的數字,另外還因 SENKU 指定再加 10% 的加成。所以我們對這次溝通非常、非常滿意。

  • In the US, and again, in Japan, we have actually patients already on therapy, physicians have actively asked for it as we were going through the pricing discussions. In the US, we got the approval. The price is available. Product is going to be on the market, I think, available actually within the next I think, 10 days or something like that, so very soon. Questions on monitoring. Did we expect it? Yes, because that monitoring exactly as described, was part of the study protocol. So we couldn't expect anything different.

    在美國,以及同樣在日本,我們其實已經有病人開始用藥;在我們進行定價討論期間,醫師也主動提出需求。在美國,我們已取得核准。價格也已公布。產品將會上市,我想實際上大概在接下來 10 天左右就能供應,所以很快。關於監測的問題。我們是否預期會這樣?是的,因為如所描述的監測本來就是研究方案的一部分。所以我們不會預期有任何不同。

  • Monitoring is there for two reasons. One is ALT elevation, so liver enzyme elevation and the other one is thrombocytopenia. Now both of those happen relatively quickly. Thrombocytopenia, specifically, I think it's even quoted in the USPI. There were two cases of severe thrombocytopenia that happens quite quickly after the initiation of therapy. And the ALT elevation is also, as described in the label, linked actually to the reduction of the surface antigen. So patients who see the reduction are definitely more likely to see ALT elevation.

    監測有兩個原因。一是 ALT 升高,也就是肝酵素升高;另一個是血小板減少症(thrombocytopenia)。這兩者通常都發生得相對快。尤其是血小板減少症,我想美國處方資訊(USPI)甚至有提到:有兩例嚴重血小板減少症是在治療開始後很快發生。而 ALT 升高也如標籤所述,實際上與表面抗原降低有關。因此,看到表面抗原降低的病人,確實更可能出現 ALT 升高。

  • Now how that monitoring is going to evolve, as I mentioned, it's quite important in the initial periods, and we do expect that physicians will monitor early, seeing if their patients are by any chance one of those who have early elevation of ALT or severe reduction of severe thrombocytopenia. And then following that, we expect that physicians and patients will find some kind of balance of when and how frequently they do monitoring.

    至於這種監測未來會如何演變,如我提到的,在初期階段相當重要;我們也預期醫師會在早期進行監測,以觀察病人是否可能屬於 ALT 早期升高或嚴重血小板減少症的個案。之後,我們預期醫師與病人會找到某種平衡,決定何時以及多頻繁地進行監測。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Nina. I think also the feedback that we're getting from experts is that sort of mentally gating the first 12 weeks and then reassessing it. So essentially, the language to the patient is, look, okay, there are frequent blood draws, and we said that to you guys in past meetings. But look, if we can get to 12 weeks, we'll reassess where you are and then continue on from that point.

    謝謝,Nina。我想我們從專家那邊收到的回饋也包括:在心理上先把前 12 週當作一個關卡,之後再重新評估。所以基本上對病人的說法是:你看,好,確實需要頻繁抽血,我們在過去的會議也跟各位說過。但如果我們能撐過 12 週,我們就會重新評估你目前的狀況,然後再從那個時間點繼續。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Maybe it's important just for you to think how it's going to work. The first dose is administered in the physician's office and then the patient gets a pack of four doses that they will self-administer at home, and they will need to obviously arrange the monitoring within that period.

    也許重要的是,你需要想清楚它將如何運作。第一劑會在醫師診間施打,之後病人會拿到一包四劑,回家自行施打,並且顯然需要在那段期間安排監測。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Tony, anything to add?

    Tony,還有要補充的嗎?

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Worthwhile just underscoring a few things. In terms of thrombocytopenia. As Nina mentioned, only two patients with severe cases, 8% had lower platelet counts, that's easily managed through dose holding. And then on the ALT flares, more than half of the functional cure patients had a flare. So it's a really important sign of potential response.

    值得再強調幾點。就血小板減少症而言。如 Nina 提到的,只有兩位病人屬於重度個案,8% 的病人血小板計數較低,透過暫停給藥即可輕鬆管理。至於 ALT 升高(flare),超過一半達到功能性治癒的病人出現了 flare。因此這是一個非常重要、顯示可能反應的訊號。

  • You're going to hear more from us on Hibsago at AASLD. So I might I'll just give you a quick summary of that now, which is the long-term sustained data out to 48 weeks. The surface antigen measurement at 12 weeks is a predictor of functional cure, retreatment modeling for future approaches. And then lastly, continued description of surface antigen loss versus health outcome, worth emphasizing that this is a disease with significant morbid and mortality outcomes.

    你們會在 AASLD 聽到我們更多關於 Hibsago 的內容。所以我現在先給各位一個快速摘要,也就是長期持續性數據可追蹤到 48 週。12 週時的表面抗原測量可作為功能性治癒的預測因子,並可用於未來策略的再治療建模。最後,會持續說明表面抗原消失與健康結局之間的關係;值得強調的是,這是一種具有顯著罹病率與死亡率結局的疾病。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. And I mean, I think the memory, Tony, it was over 60% of patients who are below 1,000 at baseline could get to below 100 of surface antigen for at least a year post treatment.

    是的。而且我的印象是,Tony,基線時低於 1,000 的病人中,有超過 60% 在治療後至少一年可降到表面抗原低於 100。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • That's right. More on that analysis at AASLD.

    沒錯。關於該分析在 AASLD 會有更多內容。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Okay, good. Thanks. Thanks, Simon. Next question, please.

    好的。謝謝。謝謝,Simon。請下一題。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Michael Leuchten, Jefferies.

    Michael Leuchten,Jefferies。

  • Michael Leuchten - Analyst

    Michael Leuchten - Analyst

  • Two, please. One for Julie. It sounds like there was inventory in the top line around Shingrix. Were there any other items in the third-quarter we should take into consideration? And then as we think about the guidance for the full year, you beat very nicely on SG&A, in particular, in the third-quarter, but the guidance doesn't go up. So just the pushes and pulls on why not given you do have some slight help from the royalty income and also lower net financials into the end of the year?

    兩個問題。第一個給 Julie。聽起來 Shingrix 在營收(top line)上有庫存因素。第三季還有其他項目是我們需要納入考量的嗎?另外,談到全年指引,你們在第三季的 SG&A(銷售、一般及行政費用)表現明顯優於預期,但指引並沒有上調。能否說明一下為什麼?畢竟你們年底前還有一些小幅助力,包含權利金收入以及較低的淨財務費用。

  • And then a question on, I guess, for Luke or maybe Tony and/or David, I understand there's limited amount you can say about Q4 treatment as in cap treatment and the read across from the PrEP, but it's the same tech, it's the same product. You clearly had an outcome with the PrEP data, the PK/PD study that didn't exactly tell you what you were hoping for and you're saying there is no read across into treatment. Like how can you make that statement? Like how can you give us confidence that there isn't any read across?

    另外一個問題,我想是給 Luke,或是 Tony 和/或 David:我理解你們對於第四季治療(cap treatment)以及從 PrEP 的對照推論能說的有限,但這是同樣的技術、同樣的產品。你們在 PrEP 數據上,也就是 PK/PD 研究,得到的結果並不完全如你們所期望,而你們卻說這不會對治療有任何對照推論。你們怎麼能做出這樣的說法?你們如何讓我們有信心,確實不存在任何對照推論?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Tony, do you want to, well, Julie will go with inventory. And then David, and David, you go on the PrEP answer and then Tony, feel free to add anything technically if you want.

    好的。Tony,你要不要先——Julie 會回答庫存的部分。然後 David,你來回答 PrEP 的問題;Tony,如果你想從技術面補充也請隨時。

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Yes. Okay. So specifically on Shingrix, I think Luke covered some of this. But in terms of sort of quantifying the US inventory build in the third-quarter, in the quarter, it amounts to about 2-percentage-points of global growth. And you do get these swings, as you know. Very confident though in the overall picture for Shingrix. And I think China, Luke has touched on this. It's all about injections in arms, and we anticipate shipping again in 2027. So I think that covers Shingrix.

    好的。就 Shingrix 而言,我想 Luke 已經涵蓋了一部分。但若要量化第三季美國庫存增加的影響,在該季度約相當於全球成長的 2 個百分點。如你所知,這類波動是會出現的。不過我們對 Shingrix 的整體情況非常有信心。至於中國,Luke 也提到過,關鍵在於實際施打量(打進手臂的針數),我們預期會在 2027 年再次出貨。

  • In terms of the third-quarter and the beat versus consensus, first of all, we appreciate it was difficult to forecast the third-quarter, many moving parts, including the acquisition of Nuvalent. And there are a few things to flag about the third-quarter. Sales were higher than our original expectations, and this included some phasing between Q3 and Q4. As we mentioned, we have the US Shingrix inventory build, meningitis ordering patterns, and we also had Ventolin impacting the quarter.

    就第三季以及相對於市場共識的優於預期而言,首先我們理解第三季確實很難預測,變動因素很多,包括 Nuvalent 的收購。第三季有幾點需要特別說明。銷售高於我們原先的預期,其中也包含 Q3 與 Q4 之間的一些時點分配(phasing)。如我們提到的,美國 Shingrix 的庫存增加、腦膜炎產品的訂購模式,以及 Ventolin 也對本季造成影響。

  • The operating profit in Q3 was impacted by SG&A phasing, better royalties, as you mentioned, partially offset by the phasing of R&D, which was very high. It was a peak growth in R&D in the third-quarter of 22%. So if we move now, obviously, we're comfortable with the overall guidance for the full year. We do expect sales growth to moderate slightly, partly HIV pricing, partly we've talked about Shingrix because last year, we had a shipment going out in the fourth-quarter to China.

    第三季的營業利益受到 SG&A 時點分配、較佳的權利金(如你所提)影響,但部分被研發費用(R&D)時點分配所抵銷,研發費用非常高。第三季研發費用成長達到高峰,年增 22%。因此接下來,我們對全年整體指引當然是有把握的。我們確實預期銷售成長會略為放緩,部分原因是 HIV 定價,部分則如我們談到的 Shingrix,因為去年第四季有一批出貨到中國。

  • And then we're also lapping some of the French and Japanese launches outside the US And then I think finally, when you think about SG&A, we're going to have the launches to support for Hepzato and Hibsago and Nuvalent. But at the same time, there was a charge last year in SG&A of about GBP0.2 billion that will not repeat in the fourth-quarter of this year. Okay?

    此外,我們也正在與美國以外市場的法國與日本上市週期做比較基期(lapping)。最後,談到 SG&A,我們將需要支援 Hepzato、Hibsago 以及 Nuvalent 的上市推進。但同時,去年 SG&A 有一筆約 2 億英鎊(GBP0.2 billion)的費用在今年第四季不會重複發生。好嗎?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Julie. And David, Michael's second question?

    謝謝,Julie。David,Michael 的第二個問題呢?

  • David Redfern - Chief Strategy Officer

    David Redfern - Chief Strategy Officer

  • Yes. I mean I think what I can say, Michael, is EXCEPT which is the PrEP study and CUATRO, which is the treatment study, are very different studies. So EXTEND is a PK bridging study where we're looking at drug substance levels at steady state, no earlier than month 13 as well as safety and tolerability. The CUATRO study is an efficacy study comparing the four-monthly formulation of cabotegravir and rilpivirine with two-monthly Cabenuva. So they're very different studies. We're very confident in the formulation that we've got. I'll probably leave it at that.

    好的。Michael,我能說的是,EXCEPT(也就是 PrEP 研究)與 CUATRO(也就是治療研究)是非常不同的研究。EXTEND 是一項 PK 橋接研究,我們觀察的是穩態下的藥物原料(drug substance)濃度,時間點不早於第 13 個月,同時也評估安全性與耐受性。CUATRO 則是一項療效研究,比較每四個月一次的 cabotegravir 與 rilpivirine 配方,對照每兩個月一次的 Cabenuva。所以它們是非常不同的研究。我們對目前的配方非常有信心。我大概就先說到這裡。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. I think the key thing here, Michael, we don't want to front-run discussions with a regulator that tends to backfire. So again, as I said earlier, we're telling you as much as we can at this point, but in the interest of long-term value creation, I'll limit it to that at this point. And I appreciate your understanding. And the second we can update you, we will.

    是的。Michael,這裡的關鍵是,我們不希望在與監管機關的討論之前搶先放話,因為那往往會適得其反。所以如我先前所說,我們在此刻已盡可能告訴各位我們能說的內容,但基於長期價值創造的考量,我目前就先限制在這個程度。也感謝你的理解。一旦我們可以更新資訊,我們會立刻更新。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Kerry Holford, Berenberg.

    Kerry Holford,Berenberg。

  • Kerry Holford - Analyst

    Kerry Holford - Analyst

  • I'm sorry, just a very quick follow-up on Apretude 4M. Just interested to know whether you do have a date scheduled to review that data with the FDA, whether you can share that with us. Ultimately, when can we expect more clarity on the issues here in the next steps?

    抱歉,我只想就 Apretude 4M 做一個非常快速的追問。想了解你們是否已排定與 FDA 檢視該數據的日期,若可以的話能否與我們分享?最終而言,我們何時可以期待在下一步與相關議題上有更清楚的資訊?

  • And then if we think into next year, and I appreciate you won't be wanting to give guidance at this point, but just given the commentary you made, Julie, on the OpEx in Q4 in the context of those Phase III starts this year and at least I think you highlighted six additional Phase IIIs starting next year. How confident are you that the necessary incremental R&D spend moving into next year can be offset by SG&A savings and COGS savings in 2027?

    另外,若我們展望明年,我理解你們此刻不想提供指引,但就你剛才的評論而言,Julie,關於第四季的營運費用(OpEx),在今年啟動那些第三期試驗的背景下,而且我記得你提到明年至少還會再啟動六項第三期試驗。你們對於明年研發費用(R&D)所需的增量支出,能夠被 SG&A 節省以及 2027 年的 COGS(銷貨成本)節省所抵銷,有多大信心?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Thanks. David, do you want to go to first? Then we will go to Julie.

    是的。謝謝。David,你要先開始嗎?然後我們再請Julie。

  • David Redfern - Chief Strategy Officer

    David Redfern - Chief Strategy Officer

  • I think what I can tell you, Kerry, is, I mean, we reached steady state for the last patient only a few weeks ago, not very long ago. So the analysis, as we've said, is ongoing. I think we are confident we will be sharing the data with the regulator before the end of the year. And obviously, post regulatory discussions, we will update appropriately. So that's sort of timing, but I can't be more specific than that.

    Kerry,我想我能告訴你的是,我的意思是,我們在幾週前才剛讓最後一位病人達到穩態,時間並不久。所以如同我們所說,分析仍在進行中。我想我們有信心會在年底前把資料分享給監管機關。而且很明顯地,在監管討論之後,我們會適時更新。所以時間大概是這樣,但我無法比這更具體。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, David. Julie?

    謝謝你,David。Julie?

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Yes. Thanks, Kerry, for the question. So as you know, we've got a really good track record of delivering margin accretion and at the same time, investing more and more in R&D. And this is part of the program around Accelerate Growth. So we've also got, as the business pivots more towards specialty, you do get a natural margin lift because the SG&A cost associated with a specialty sell is considerably lower than it would be if you were in primary care. So both of these are major factors.

    是的。謝謝Kerry的提問。如你所知,我們在提升利潤率(margin accretion)的交付上有非常好的紀錄,同時也持續加大對研發(R&D)的投資。而這是「加速成長」(Accelerate Growth)計畫的一部分。另外,隨著業務更轉向專科領域,你會自然看到利潤率上升,因為專科銷售所需的SG&A成本,明顯低於基層醫療(primary care)。所以這兩點都是主要因素。

  • So we do expect R&D to continue to grow ahead of sales. You'll be pleased to know not to the extent of Q3, which was obviously very high. But as demonstrated, we can deliver profitable growth through the efficiency in both the cost of goods, and we've talked about the specialty pivot together with the SG&A. And the Accelerate Growth program is all about removing cost from what you may call support services and some of the manufacturing network, and it's moving it towards the front line of R&D.

    因此,我們確實預期研發支出會持續成長,且增速會快於銷售。你會很高興知道,不會像第三季那樣的幅度,第三季顯然非常高。但如同我們所展示的,我們可以透過在製造成本(cost of goods)上的效率提升,以及我們談到的專科轉型(specialty pivot)與SG&A,一起實現獲利性成長。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Sachin Jain, Bank of America.

    Sachin Jain,美國銀行(Bank of America)。

  • Sachin Jain - Analyst

    Sachin Jain - Analyst

  • A couple on some drivers. impact you called out on the '27 driver slide, Julie. I'm assuming this is already heavily rebated. So any color on additional IRA pressure? And the second one you can just touch on is Dovato. You talked about DTG tender impact in the quarter. Should we expect that to grow into next year? And then just one follow-up for Nina on Hibsago China. Very clear on approval time lines. Can you just run us through time lines for reimbursement? I assume this requires NRDL listing, et cetera. So just any color there.

    有幾個關於驅動因素的問題。Julie,你在'27驅動因素投影片中提到的影響。我假設這已經是高度回扣(rebated)後的狀況。那麼,能否談談額外的IRA壓力?第二個想請你簡單談一下Dovato。你提到本季DTG標案(tender)影響。我們是否應預期這個影響會延續並擴大到明年?另外再追問Nina一題,關於Hibsago在中國。你對核准時程講得很清楚。能否帶我們走一遍報銷(reimbursement)的時程?我假設這需要納入NRDL名單等等。所以想請你提供一些顏色(補充說明)。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Sure. So David, do you want to do Dovato first, and then we'll come back to Nina to do Trelegy and Hibsago, I think.

    當然。David,你要不要先談Dovato,然後我們再請Nina回來談Trelegy和Hibsago,我想是這樣。

  • David Redfern - Chief Strategy Officer

    David Redfern - Chief Strategy Officer

  • Sure. I mean I could be quick. I think, Sachin, I mean, Dovato, there are some international markets, notably Brazil, where the patents on dolutegravir expired this year, and that had some marginal impact, although, obviously, overall, we're very pleased with the commercial performance of ViiV growing double digits and dolutegravir overall. But there was some impact in Brazil. Actually, as you know, the composition of matter for dolutegravir in the US is 2028. Next year, we don't really have any other significant markets where we lose patents. So we expect most of the trends to continue.

    可以。我可以簡短說明。Sachin,我的意思是,Dovato在一些國際市場,特別是巴西,dolutegravir的專利今年到期,這帶來了一些邊際影響;不過很明顯地,整體而言,我們對ViiV的商業表現非常滿意,ViiV維持雙位數成長,而dolutegravir整體也是如此。但巴西確實有一些影響。另外,如你所知,dolutegravir在美國的物質組成(composition of matter)專利到2028年。明年我們沒有其他會失去專利的重要市場。所以我們預期大多數趨勢會延續。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Nina, do you want to start with Hibsago and then we come to Trelegy.

    Nina,你要不要先從Hibsago開始,然後我們再談Trelegy。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yes. So Hibsago China, as I said, discussions are ongoing. I'm not sure I want to commit to a specific time line because what we have seen is a huge desire from the Chinese authorities to make the drug available. I expect it's going to be sooner than what we planned, but let's leave it with that. We are going to launch immediately. We will launch in the private market in China as it becomes available. And then with the next round of NRDL discussions, it will be included. I hope by the end of next year, we should be there.

    好的。關於Hibsago在中國,如我所說,討論仍在進行中。我不確定我是否想承諾一個具體時程,因為我們看到中國主管機關非常希望讓這個藥物可及。我預期會比我們原先規劃的更快,但就先說到這裡。我們會立即上市。一旦可供應,我們會先在中國的自費市場(private market)推出。接著在下一輪NRDL談判中,會把它納入。我希望到明年年底,我們應該就能達成。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. And I think on Trelegy, we just have to rebase it. I mean, as you know, it was added to the list for CMS in, I think, November '25. So, the negotiated price for 30 days is now $175, which is a 73% discount to the '24 list price. So there will be a one-off impact in the US. We'll rebase that and then position B on that. Again, we're being thoughtful in terms of how we resource this product in the US Julie, anything you want to add on that?

    是的。至於Trelegy,我們必須重新定基(rebase)。如你所知,它在我記得是2025年11月被CMS納入名單。因此,30天的協商價格現在是175美元,相較於2024年的牌價(list price)折扣73%。所以在美國會有一次性的影響。我們會把基準重設,然後在此基礎上做定位(position B)。同樣地,我們在美國如何配置這個產品的資源方面也會審慎思考。Julie,你有什麼要補充的嗎?

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Thanks, Luke. Obviously, just to say that the WAC price reduction, clearly, this is a product in its more mature phase. So there are rebates and returns associated with it. So net-net, not quite as significant as Luke indicated, totally included in our guidance. We judged it fairly well a number of years ago, and it was built into the long-term forecast.

    謝謝,Luke。很明顯地,我想補充的是WAC價格下調;顯然,這是一個處於較成熟階段的產品。因此會有與之相關的回扣與退貨(rebates and returns)。所以淨額(net-net)來看,影響沒有Luke所說的那麼大,且已完全納入我們的指引(guidance)。我們在幾年前就相當準確地判斷了這點,並已納入長期預測。

  • In terms of, we've also got Breo alongside Trelegy impacting in 2027, together with the Biktarvy royalty stream that comes off in October in '27, which is a headwind of around GBP70 million a quarter. And those are the main things. We've actually included a slide to help. We know you will be focused more and more on 2027. We have included a slide on modeling considerations in the appendix for those who have not seen it just yet.

    另外,就影響而言,我們還有Breo與Trelegy一起在2027年受到影響,再加上Biktarvy的權利金收入(royalty stream)在2027年10月到期,這大約是每季7,000萬英鎊的逆風。這些就是主要項目。我們其實也加入了一張投影片來協助說明。我們知道你們會越來越聚焦在2027年。對於尚未看過的人,我們在附錄中放了一張關於建模考量(modeling considerations)的投影片。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Right. Thanks, Julie. Should we keep going, Jeff? I'm sure we've got people with questions on. If you guys are happy to keep running, we can run for another, say, 10 or 15.

    好。謝謝,Julie。Jeff,我們要繼續嗎?我相信還有人有問題。如果大家都願意繼續,我們可以再進行大概10到15分鐘。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Zane Ebrahim, JPMorgan.

    Zane Ebrahim,摩根大通(JPMorgan)。

  • Zain Ebrahim - Analyst

    Zain Ebrahim - Analyst

  • Just a follow-up on the previous question in terms of if we think about the totality of the IRA headwind for both Breo and Trelegy, is the consensus outlook for general medicines in the right sort of place for next year? I know you said it's broadly in line with your forecast, but just if you could clarify that, that would be helpful. And then on Hibsago, I noticed you mentioned that you've got some clarity on the pricing.

    就前一個問題再追問一下:如果我們把Breo和Trelegy兩者的IRA逆風合併來看,市場共識對明年一般藥品(general medicines)的展望是否大致在正確的位置?我知道你說大致與你們的預測一致,但如果你能釐清一下會很有幫助。另外關於Hibsago,我注意到你提到你們對定價已有一些明確性。

  • So how does that compare versus your initial expectations for Hep C-like pricing in the US that is? And just remind us on what proportion of the population here is Part D and when we can expect Part D inclusion?

    那這與你們最初對美國類似丙肝(Hep C-like)定價的預期相比如何?另外也請提醒我們,這裡有多少比例的人口屬於Part D,以及我們何時可以預期納入Part D?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes, sure. So I'll just, I mean, on pricing, it's about GBP50,000 in Japan, just over GBP100,000 in the US. And just, actually, I'll give you some epi because I think it would be helpful. So US is about 1.7 million patients, 400,000 diagnosed, 120,000 treated. Japan is, sorry, 0.9 million. Of those 600,000 are diagnosed and 120,000 are treated. So similar and China, about 6 million treated. So it's in a category of own, but obviously, access and pricing is different there. Julie, did you want to cover anything on beyond what we can say as it is forward-looking?

    是的,當然。所以我就簡單說一下,我是說在定價方面,日本大約是5萬英鎊,美國則是略高於10萬英鎊。而且其實我給你一些流行病學(epi)數據,因為我覺得會有幫助。美國大約有170萬名患者,40萬名已確診,12萬名正在接受治療。日本是,抱歉,是90萬。其中60萬名已確診,12萬名正在接受治療。所以情況相近;而中國大約有600萬名正在接受治療。所以它屬於一個獨特的類別,但顯然,那裡的可及性與定價是不同的。Julie,你想就我們能說的、且屬於前瞻性陳述以外的部分補充什麼嗎?

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • I think at this stage, we'll concentrate on giving you comprehensive guidance at the end of the year, certainly by product area or product category. We'll come back to that.

    我想在這個階段,我們會專注於在年底給你們提供全面的指引,當然會按產品領域或產品類別來提供。我們會再回到這點。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Anything you want to add on Hibsago, Part D? As well, I mean on commercial, Nina?

    你有什麼想補充關於Hibsago、Part D的嗎?另外,我是說在商業端方面,Nina?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Most of these patients have, do have commercial coverage. So and there is no competition. which is relevant for this, to which extent the pricing the discounts go. There's just no alternative, which definitely helps.

    這些患者大多數確實有商業保險覆蓋。而且沒有競爭。這對於折扣在多大程度上影響定價是相關的。就是沒有替代方案,這肯定有幫助。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. And the cost of these patients, obviously, as the disease progresses. I mean, look at the market research, and it makes sense. I think physicians are going to concentrate on the younger patients initially and build that experience there with them. And as Nina said, I mean, I think 2031 is the earliest entrant, excluding China that we would expect to be there. And of course, there's a history of combinations and failure in this area. So let's see how these combinations evolve in time.

    是的。而且這些患者的成本,顯然會隨著疾病進展而上升。我是說,看看市場調研,這是合理的。我認為醫師一開始會把重點放在較年輕的患者身上,並在他們身上建立使用經驗。而且如Nina所說,我是說,我認為2031年是我們預期最早的進入者(不含中國)。當然,這個領域在聯合療法與失敗方面是有歷史的。所以讓我們看看這些聯合療法隨時間如何演進。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Matthew Weston, UBS.

    Matthew Weston,瑞銀(UBS)。

  • Matthew Weston - Analyst

    Matthew Weston - Analyst

  • Two questions, please. I hear your confidence in Exdensur, but Nucala was also weak in 3Q as well. Can I understand if you've offered on the additional access you're talking about on Exdensur or whether or not it's pressure overall in the IL-5 category as physicians prefer TSLP?

    兩個問題,謝謝。我聽到你們對Exdensur很有信心,但Nucala在第三季也偏弱。我想了解一下:你們所說的Exdensur額外可及性,是否已經透過讓利/讓價來換取?還是說整體IL-5類別正面臨壓力,因為醫師更偏好TSLP?

  • And then secondly, Julie, it's a Joe Walton memorial question. On 2027 net financial charge, you've highlighted the strong cash flow, but obviously, the cash out for Nuvalent and for the restructuring program, do you think that consensus has next year's net financial charge modeled correctly or we need to sharpen our pencils?

    第二個問題,Julie,這是一個「Joe Walton紀念題」。關於2027年的淨財務費用,你們強調了強勁的現金流,但顯然,Nuvalent以及重組計畫都有現金流出。你覺得市場共識對明年淨財務費用的建模是否正確?還是我們需要把鉛筆削尖一點(重新估算)?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • No worries. Thanks, Matthew. So just quickly on Nucala. I mean, if you look at the numbers in the US volume, I think, was up nearly 39%, price is down 15%. So there is some pressure there. I would be cautious about reading that across to Exdensur. So one of the things we've been quite deliberate on, which is holding the line on Exdensur pricing. We want to take a long-term view here. We've got a long-acting TSLP. We've got a long-acting IgE. We've got a long-acting IL-33.

    沒問題。謝謝你,Matthew。先快速談一下Nucala。我是說,如果你看美國的數據,銷量我認為上升了將近39%,價格下降了15%。所以確實有一些壓力。但我會謹慎,不要把這直接套用到Exdensur上。我們一直相當刻意在做的一件事,就是守住Exdensur的定價底線。我們希望採取長期視角。我們有長效型TSLP、長效型IgE,以及長效型IL-33。

  • So if you look at coverage, I mean, in terms of commercial parity to say, Nucala or benralizumab, we've gone from 18% in Q2 to 43% in Q3. And overall, we've got 71% of lives covered with the difference being some step through. So that's been deliberate there. I think there is clearly competitive pressure from TSLP overall on the class, but that is also being offset to a degree with COPD and COPD is helping us within the IL-5 class capture business. Nina, anything that you want to add on that? No?

    所以如果你看覆蓋情況,我是說,就商業保險覆蓋與Nucala或benralizumab的同等性而言,我們已從第二季的18%提升到第三季的43%。而整體而言,我們有71%的人群(lives)已被覆蓋,差異在於部分需要先行階梯治療(step through)。所以這是我們刻意的安排。我認為整體來看,TSLP對這個類別確實帶來競爭壓力,但在某種程度上也被COPD所抵消,而COPD正在幫助我們在IL-5類別中拿到業務。Nina,你有什麼想補充的嗎?沒有?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Again, just remember, Q3 for patient visits is the weakest quarter in the year.

    再提醒一下,第三季的患者就診量是一年中最弱的一季。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Julie?

    是的。Julie?

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Yes. So yes, just in terms of the interest charges that are coming through. And you're right, the, obviously, we've had some considerable cash outflows, particularly in the second half of the year with the Nuvalent acquisition and accelerate growth. The good news is it's moving at pace. So we're anticipating charges this year. We originally guided GBP0.7 billion. We're expecting now charges in the order of GBP1 billion. This is P&L. And obviously, that's going to affect the cash flow going into next year.

    是的。所以是的,就利息費用的部分來說。你說得對,顯然我們有一些相當可觀的現金流出,特別是在下半年,包含Nuvalent的收購以及加速成長。好消息是進展很快。所以我們預期今年會有相關費用。我們原先指引是7億英鎊。我們現在預期費用大約在10億英鎊的量級。這是損益表(P&L)上的費用。而且顯然,這會影響到進入明年的現金流。

  • So in terms of the financial charge, we've guided for the second half of this year that Nuvalent will be GBP160 million. So it gives you an idea about how much it will cost us next year in terms of interest. It's going to be over GBP300 million. And then in terms of the overall interest charge, I mean, I'll guide this at the end of the year, but it's going to be in the order of GBP900 million to maybe GBP1 billion. Rates are adverse at the moment as well, which is, the team did a great job of financing Nuvalent when we did, but the rates are getting harder.

    所以就財務費用而言,我們已指引今年下半年Nuvalent將是1.6億英鎊。這能讓你大致了解明年就利息而言會花多少成本。會超過3億英鎊。至於整體利息費用,我是說,我會在年底給出指引,但大概會在9億英鎊到可能10億英鎊的量級。目前利率也不利;團隊在我們當時為Nuvalent融資時做得非常好,但利率環境正在變得更艱難。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • And I guess with the topic of Nuvalent, can I make a request for people have got questions on oncology. We've just had I think a remarkable ESMO. So I don't know, Jeff. Hopefully, someone's got a question on oncology next.

    我想既然談到Nuvalent,我可以請求一下:如果有人對腫瘤領域有問題。我們剛剛在ESMO上我認為表現非常出色。所以我不知道,Jeff。希望接下來有人會問腫瘤相關的問題。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • Yes. Well, next up, we'll go with Graham Parry. You're not number five. You're up next.

    是的。那接下來我們請Graham Parry。你不是第五位。你下一位。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Hi, Graham. You asked what you want, Graham.

    嗨,Graham。你想問什麼就問吧,Graham。

  • Graham Parry - Analyst

    Graham Parry - Analyst

  • Yes, I asked my oncology questions yesterday, I'm afraid. So I'm just going to go back to the EXTEND4M and just if you can help us understand what it is that needs fully characterizing about the new formulation. And can you just remind us, I think this was the study for monthly dosing was actually determined from PK simulations from the Phase I CAB LA study that you presented at CROI in 2024. So is really this just that the PK isn't matching what your simulations were showing? Or is this an issue of tolerability because I think you just had sort of single administration tolerability data on that.

    是的,我昨天已經問過我的腫瘤問題了,抱歉。所以我想回到EXTEND4M,想請你們幫我們理解:這個新配方到底有哪些部分需要被完整表徵(fully characterizing)?另外你們能否提醒我們:我記得這個每月給藥的研究,其實是根據你們在2024年CROI上展示的第一期CAB LA研究的PK模擬所決定的。所以這實際上是PK沒有符合你們模擬所顯示的結果嗎?還是這是耐受性方面的問題,因為我記得你們當時只有單次給藥的耐受性數據。

  • And then can you also clarify that it is the same formulation in CUATRO? I think there's a bit of confusion about that based on your comments that this doesn't read through to CUATRO. So although they are different studies and one is an efficacy study, if there's a PK or tolerability issue with EXTEND4M, why wouldn't that then translate to CUATRO? And then my final question is just thoughts on Arbutus Bio litigation update. You've now had the post-trial hearing. Are we heading towards a negotiated settlement here? Or are you waiting for a ruling?

    然後你們也能否澄清:CUATRO使用的是同一個配方嗎?我想基於你們說「這不會延伸影響到CUATRO」的評論,大家對此有些混淆。所以雖然它們是不同研究、其中一個是療效研究,但如果EXTEND4M存在PK或耐受性問題,為什麼不會同樣反映到CUATRO?最後一個問題是關於Arbutus Bio訴訟的最新進展。你們現在已經完成了審後聽證(post-trial hearing)。我們是否正走向協商和解?還是你們在等待裁決?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Graham. Well, I think on the second question, I would direct you to the share price on the day. And I can't say much more than that. at this point. David, again, I'm not sure you can add too much more. We would love to tell you more, but again, we don't want to prejudice our discussions with regulators, but.

    謝謝你,Graham。嗯,我想針對第二個問題,我會請你看一下當天的股價表現。除此之外我也沒辦法多說。在目前這個時間點。David,再次強調,我不確定你是否能再補充太多。我們很希望能告訴你更多,但同樣地,我們不想影響我們與監管機構的討論,但。

  • David Redfern - Chief Strategy Officer

    David Redfern - Chief Strategy Officer

  • Yes. I mean I think that's right. I think we need to do the analysis and then we need to talk to the regulators. So I'm not going to go into much detail. I mean what I can say, Graham, is you're right on the PK levels were set based on the pivotal study that we did for two-monthly. And you're right that it's the same formulation in both Xtend and CUATRO. We are very confident in that formulation.

    是的。我的意思是,我想你說得對。我想我們需要先做分析,然後再和監管機構溝通。所以我不會深入太多細節。我的意思是,我能說的是,Graham,你說得沒錯,PK 水準是根據我們針對每兩個月給藥所做的關鍵性研究來設定的。而且你也說得對,Xtend 和 CUATRO 兩個研究使用的是相同配方。我們對該配方非常有信心。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • And I think we've said it several times, there's no read across. No. Okay. Thank you. Did we cover every one of Graham's questions? We did.

    而且我想我們已經說過好幾次了,兩者之間不能相互推論(no read across)。不。好的。謝謝。我們有把 Graham 的每個問題都回答到嗎?有。

  • Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

    Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations

  • I think we got Graham. Yes. Maybe time for one more question. Let's go with Trung from RBC.

    我想我們已經回覆 Graham 了。是的。也許再來一個問題的時間。我們請 RBC 的 Trung。

  • Trung Huynh - Analyst

    Trung Huynh - Analyst

  • Unfortunately, no oncology question here either, but -- we did have a couple of pipeline at once though.

    很可惜,這裡也沒有腫瘤學的問題,不過——我們確實有幾個管線問題。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • You covered a lot.

    你們涵蓋了很多。

  • Trung Huynh - Analyst

    Trung Huynh - Analyst

  • You answered them all yesterday. So on food allergy, you've got the [ Exdensur ]Phase II data next year. How you're thinking about the opportunity here? The competitive landscape does seem like it's evolving somewhat. There's perhaps more Xolair generic entry. Remi is moving into Phase III.

    你們昨天都回答完了。所以在食物過敏方面,你們明年會有 [ Exdensur ] 的第二期數據。你們如何看待這裡的機會?競爭格局看起來確實正在某種程度上演變。可能會有更多 Xolair 的學名藥進入。Remi 正在進入第三期。

  • So just what's your view on how that market develops and where [ Exdensur ] can differentiate there? Then the second one is just on the agreement with Hansoh. So one of those assets is a PDE3/4 in COPD. Just can you provide a bit more detail on some of the other targets that you're evaluating in this collaboration? When can we expect the next programs to be option? How can we think about milestones, economics as things progress?

    所以你們怎麼看這個市場的發展,以及 [ Exdensur ] 在那裡可以如何差異化?第二個問題是關於與 Hansoh 的協議。其中一個資產是用於 COPD 的 PDE3/4。你們能否就這項合作中正在評估的其他一些標的提供更多細節?我們何時可以期待下一批專案進入可選擇(option)的階段?隨著進展,我們應如何看待里程碑與經濟條款?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Sure. So thanks, Trung. I'll let Tony cover the collaboration in a second. I'll just give you, I assume you mean ozureprubart IgE, not Xolair for food allergy. So yes, basically, in '27, we'll get a IIb readout for food allergy. And the aim is to start the Phase III in the second half of next year. Look, this is a huge opportunity. There's about 17 million people in the US that have some form of food allergy and about 1.6 million of them have what we term as clinically relevant disease.

    當然。謝謝你,Trung。我等一下讓 Tony 來談合作。我先回覆你——我猜你指的是 ozureprubart IgE,而不是用於食物過敏的 Xolair。所以是的,基本上在 2027 年,我們會拿到食物過敏的 IIb 期讀出。目標是在明年下半年啟動第三期。你看,這是一個巨大的機會。美國大約有 1,700 萬人有某種形式的食物過敏,其中約 160 萬人屬於我們所稱的具臨床意義的疾病。

  • So, and you're all very familiar with the growth that Xolair seen. When we did this deal, we actually modeled that there would be up to four biosimilars entering in our calculations. Again, there are some structural limits. I mean it's about 1/4 of patients on Xolair where essentially the Xolair, the maximum approved Xolair dose just can't find enough IgE to be effective in these heavier larger individuals. So we've got a product that's essentially twice the potency of Xolair.

    而且各位都很熟悉 Xolair 所呈現的成長。我們做這筆交易時,實際上在模型計算中已納入最多可能有四個生物相似藥進入的情境。同樣地,仍有一些結構性的限制。我的意思是,大約有 1/4 的 Xolair 病人,基本上是因為已核准的 Xolair 最高劑量在這些體重較重、體型較大的個體身上,無法捕捉到足夠的 IgE 而達到效果。因此我們有一個產品,其效力基本上是 Xolair 的兩倍。

  • And yes, it could be a three-monthly shot with either three doses or an upside scenario, one dose. Look, I think we've covered the BTK, two tablets a day. You've got the tox heritage of BTKs. XL111, it's Phase I is due at the end of the year. So I think you need to risk adjust that, and it's really a long way behind.

    而且是的,它可能是每三個月打一針,可能需要三劑;在更樂觀的情境下,可能只要一劑。你看,我想我們已經談過 BTK,一天兩顆。BTK 類藥物有其毒性方面的既有背景(tox heritage)。XL111 的第一期預計在年底出結果。所以我想你需要做風險調整,而且它其實還落後很遠。

  • So yes, I think we've got a very, very nice asset here. We've got a very deliberate development plan. It's properties that behaves the same way it binds the same way as Xolair. So factor that in and that, again, is part of our BD strategy. So yes, I think we're encouraged with the profile that we see. Anything you want to add on that, Tony, before we go to Hansoh?

    所以是的,我認為我們這裡有一個非常、非常不錯的資產。我們有一個非常審慎的開發計畫。它的性質與行為方式、以及結合方式都和 Xolair 相同。所以把這點納入考量;而這同樣也是我們 BD 策略的一部分。所以是的,我們對目前看到的特性(profile)感到鼓舞。在我們轉到 Hansoh 之前,Tony,你還想補充什麼嗎?

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • No, I think you've covered it well. I mean that was all about the nomogram simplification and getting to the higher weight patients as well, as Luke said. And then on Hansoh, the PDE3/4 is in early clinical development. This is very much looking for metered dose inhaler opportunity for that particular approach, and you'll be aware of the early clinical data in the area from competitors that suggest that it's an effective mechanism. We were very careful to look for a molecule that had a similar profile.

    沒有,我想你已經講得很完整了。我的意思是,這主要是關於列線圖(nomogram)的簡化,以及如 Luke 所說,也能涵蓋到體重較高的病人。至於 Hansoh,PDE3/4 目前仍在早期臨床開發。這個方向非常著重於尋找該機制的定量噴霧吸入器(metered dose inhaler)機會;你也會知道,競品在這個領域的早期臨床數據顯示這是一個有效的作用機制。我們非常謹慎地尋找一個具有相似特性(profile)的分子。

  • We've got 11 other targets in the collaboration. They haven't been disclosed, but it's fair to say that we're engaged very actively with Hansoh on selecting the next range of those for disclosure. I'm very pleased with the options that we have in front of us.

    在這項合作中我們還有另外 11 個標的。目前尚未對外揭露,但可以說,我們正非常積極地與 Hansoh 合作,挑選下一批要揭露的項目範圍。我對我們目前面前的選項感到非常滿意。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Great. Thanks, Tony. I think we should conclude. We're 11 minutes over. Thank you, everyone, again, for very thoughtful questions. I appreciate you dialling in.

    很好。謝謝你,Tony。我想我們應該要結束了。我們已經超時 11 分鐘。再次感謝各位提出非常有深度的問題。也感謝各位撥冗參與電話會議。